Amatoxin analogs and uses thereof

The new synthetic route for dihydroxyisoleucine analogs addresses the challenges in producing amatoxin components, enabling efficient synthesis and application in cancer therapies by modifying the sidechain and protection groups, thus enhancing the production and therapeutic potential of amatoxin analogs.

WO2024243706A1PCT designated stage expired Publication Date: 2024-12-05THE UNIV OF BRITISH COLUMBIA
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2024/050737
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The synthesis of dihydroxyisoleucine, a crucial component for amatoxin analogs, faces challenges due to its complex structure and the inefficiencies in existing synthetic routes, including low yields, diastereoselectivity issues, and safety concerns, hindering the production of amatoxin-targeted therapeutics.

Method used

A new synthetic route for (2S,3R,4R/S)-dihydroxyisoleucine analogs is developed, which includes specific modifications to the sidechain and protection groups, allowing for the formation of amatoxin analogs that can be conjugated with linkers for targeted cancer therapy, enhancing the accessibility and efficiency of amatoxin-based treatments.

Benefits of technology

This route facilitates the production of amatoxin analogs in larger quantities, improving the synthesis of valuable intermediates and enabling their use in antibody-drug conjugates for cancer treatment by overcoming previous synthetic hurdles.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CA2024050737_05122024_PF_FP_ABST
    Figure CA2024050737_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates, for example, to amatoxin analogs containing di- hydroxyisoleucine (DHIle) analogs and optionally additional handles for bioconjugation as well as methods for their preparation, constructs comprising such amatoxin analogs coupled to a linker and conjugates comprising such amatoxin analogs or amatoxin-linker constructs. The present disclosure also relates to uses of such amatoxin analogs, for example, in treatment of cancer. For example, the amatoxin analog can be a compound of Formula I.
Need to check novelty before this filing date? Find Prior Art

Description

AMATOXIN ANALOGS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the benefit of priority from co-pending U.S. provisional application no. 63 / 470,542 filed on June 2, 2023, the contents of which are incorporated herein by reference in their entirety. FIELD

[0002] The present disclosure relates, for example, to amatoxin analogs, methods for their preparation, conjugates comprising such amatoxin analogs and their use, for example, in the treatment of cancer. BACKGROUND

[0003] α-Amanitin is an extremely toxic bicyclic octapeptide extracted from the death- cap mushroom, Amanita phalloides. It exhibits impressive oral bioavailability and excellent toxicity, thus making it one of the most lethal natural products known to humankind (LD50= 50-100 µg / kg). It is an allosteric, selective, and potent inhibitor of RNA polymerase II (Ki of 1-10 nM), the enzyme indispensable for cellular function and homeostasis. Since RNA polymerase II catalyzed transcription is obligatory for cellular viability, it empowers α- amanitin to target actively dividing and quiescent cells. With the appealing properties of stability, potency, and a unique mechanism of action, it has shown formidable promise as a payload in antibody-drug conjugates (ADCs) for cancer treatment.

[0004] Extraction from mushrooms has emanated the amanitin for ADC with low yields. Therefore, it is desirable to design a synthetic route for cytotoxic amanitin to enhance the application of amanitin-targeted therapeutics. However, accessing synthetic amanitin includes numerous synthetic hurdles with di-hydroxy isoleucine being one of the prominent synthetic challenges. It is a chiral, oxidized, non-canonical amino acid indispensable for toxicity. It is a high functional density molecule containing a carboxylic acid, an amine, diols, and β-branched methyl on a five-carbon linear main chain, thereby making the synthesis extensive and arduous.

[0005] Among the notable synthetic challenges associated with di-hydroxy isoleucine is accessing di-hydroxy isoleucine for use in solid phase peptide synthesis (SPPS). Embedded in this deceptively simple amino acid are challenges including those summarized in Scheme 1.Scheme 1. Exemplary challenges associated with synthesis of DHIle.

[0006] Following the first racemic synthesis of DHIle in 1966 (Georgi & Wieland), diastereoselective approaches were reported in the 1980s (Bartlett et al., 1982; Zhao et al., 2015). Yet it wasn’t until 2018 that the first enantioselective route was reported. With the disclosure of several routes since 2018, the quest for a robust and efficient synthetic pathway for DHIIe has become a topic of shared interest. Perrin et al. used Brown crotylation to set the desired configuration at C3 and C4, yet this reaction proved costly and not readily scalable (Matinkhoo et al., 2018). Furthermore, the subsequent Upjohn dihydroxylation issued osmium waste. In 2021, Perrin et al. circumvented oxidative olefin cleavage with a proline-catalyzed aldol reaction to directly provide the aldehyde needed for a Strecker reaction (Hambira et al., 2021). Yet with mismatched stereochemistry, challenges persist: low diastereoselectivity ca.1.2:1, challenging separation of epimers, and the associated safety risks of using cyanide at scale.

[0007] Two approaches (Siegert et al., 2020; Lutz et al., 2020) logically anticipated late- stage dihydroxylation (DH) of a suitably protected γ,δ-dehydro-isoleucine; in practice, unliganded OsO4-catalyzed DH favored the desired diol in a diastereomeric ratio of ca.2.5:1 whereas Sharpless-AD surprisingly favored the undesired diastereomer (Siegert et al., 2020). To procure the dehydroisoleucine, Siegert et al. (2020) marshalled metal-mediated asymmetric transformations including Kazmaier’s ruthenium-catalyzed allylation of a zinc- enolate (Bayer & Kazmaier, 2014) and Zn(Cu)0-mediated reductive ring opening of 2- (iodomethyl)-3-methyl-oxirane in situ, which was procured via Sharpless asymmetric epoxidation of trans-butenol and transposed to the iodide. Lutz et al. (2020), starting with a severely N-protected aspartate diester, effected Rapoport’s diastereoselective methylation (Wolf & Rapoport, 1989) followed by over-reduction, reoxidation, and Wittig olefination to generate dehydroisoleucine, that was dehydroxylated using Sharpless AD-beta mix to afford protected DHIle with diastereomeric ratio of ca.2:1.SUMMARY

[0008] Herein is described amatoxin analogs containing (2S,3R,4R / S)-dihydroxyisoleucine (DHIle) analogs and / or handles for bioconjugation. These analogs are desirable as the amatoxins exhibit differential toxicity and have a potential application in ADCs, thereby augmenting the application of amanitin-targeted therapeutics. The new synthetic route described herein is noteworthy as it truncates the synthetic stringency toward accessing DHIle in large quantities and it also renders valuable intermediates for the synthesis of analogs.

[0009] Accordingly, the present disclosure includes an amatoxin analog comprising a DHIle residue with a sidechain of the formula: , wherein R1is H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ',- ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2; and R2is H, OR ', NHR ', SR ' or halo; or R1and R2,together with the carbon atoms to which they are attached, form epoxy; each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, or a pharmaceutically acceptable salt thereof, provided that when R1is H or OH, R2is other than H or OH, and when R2is H or OH, R1is other than H or OH; and wherein in the amatoxin analog or the pharmaceutically acceptable salt thereof, one or more available hydrogens is / are optionally replaced with deuterium and / or one or more available hydrogens is / are optionally replaced with fluorine and / or one or more available atoms is / are optionally replaced with its radioactive isotope.

[0010] In an embodiment, the amatoxin analog is a compound of Formula I: , wherein A is S, S(O), SO2, Se, Se(O) or SeO2; R1is H, OR ', NR 'R2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2; and R2is H, OR ', NHR ', SR ' or halo; or R1and R2,together with the carbon atoms to which they are attached, form epoxy; R3is OR ', NH(OR '), NH-NHR ' or N(R ')2; R4is OR ', NH(OR '), NH-NHR ' or N(R ')2; R5is H or OH; n is an integer from 0 to 4; and each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, or a pharmaceutically acceptable salt thereof; provided that when R1is H or OH, R2is other than H or OH, and when R2is H or OH, R1is other than H or OH; and wherein in the compound of Formula I or the pharmaceutically acceptable salt thereof, one or more available hydrogens is / are optionally replaced with deuterium and / or one or more available hydrogens is / are optionally replaced with fluorine and / or one or more available atoms is / are optionally replaced with its radioactive isotope.

[0011] The present disclosure also includes an amatoxin-linker construct comprising an amatoxin analog as described herein (which may include pharmaceutically acceptable salts thereof) coupled to a linker, wherein the linker comprises a reactive group R6for conjugating the amatoxin-linker construct to a target-binding moiety.

[0012] The present disclosure also includes a conjugate comprising a target-binding moiety conjugated to an amatoxin analog or an amatoxin-linker construct as described herein.

[0013] The present disclosure also includes a pharmaceutical composition comprising an amatoxin analog or conjugate of the present disclosure and a pharmaceutically acceptable carrier.

[0014] The present disclosure also includes a use of an amatoxin analog or a conjugate of the present disclosure for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target. The present disclosure also includes a use of an amatoxin analog or a conjugate of the present disclosure for preparation of a medicament for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target.

[0015] The present disclosure also includes a use of an amatoxin analog or a conjugate of the present disclosure for treatment of cancer in a subject in need thereof. The present disclosure also includes a use of an amatoxin analog of the present disclosure for treatment of cancer in a subject in need thereof. The present disclosure also includes a use of an amatoxin analog or a conjugate of the present disclosure for preparation of a medicament for treatment of cancer in a subject in need thereof.

[0016] The present disclosure also includes a dihydroxyisoleucine (DHIle) analog of the Formula II: , wherein R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; and PG1and PG2are each independently protecting groups.

[0017] The present disclosure also includes a dihydroxyisoleucine (DHIle) analog of the Formula III: , wherein R1is OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', -ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2; and each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, or a pharmaceutically acceptable salt thereof, provided that R1is not OH.

[0018] In one aspect of the present disclosure is provided an amatoxin compound of Formula I: where R1is selected from -H, -OH, -F, -Cl, -Br, -N3, -S-S-tBu, - SH, -NH2, epoxy, imidazole, -CN, -SOR, -ONH2, -NHOH, -SO2R, -SeR, and -NHNH2(where R is selected from H, Me,Et, iPr or another optionally substituted linear or branched 1-10 carbon alkyl group) and R2is either -CH2CH2N3or H.

[0019] In another aspect of the present disclosure, the amatoxin analog is selected from the following compounds: ; ; ; ;; ; and .

[0020] In another aspect of the present disclosure is provided a method for synthesizing (2S,3R,4R / S)-DHIle analogs according to Scheme 2, Scheme 4, Scheme 6, and Scheme 7.

[0021] In yet another aspect of the present disclosure are provided DHIle analogs according to the following formula: where R1is selected from -H, -OH, -F, -Cl, -Br, -N3, -S-S-tBu, -SH, -NH2, epoxy, imidazole, -CN, -SOR, -ONH2, -NHOH, -SO2R, -SeR, and -NHNH2(where R is selected from H, Me, Et, iPr or another optionally substituted linear or branched 1-10 carbon alkyl group).

[0022] In another aspect of the present disclosure the DHIle analog is selected from the following compounds: .

[0023] In another aspect of the present disclosure is provided a method for synthesizing (2 ,3R,4R / S)-DHIle analogs starting from a γ-keto-L-isoleucine precursor according to Scheme 5.

[0024] In another aspect of the present disclosure is provided a method for synthesizing (2S,3R,4R / S)-DHIle analogs from a γ-keto-L-isoleucine precursor wherein a synthetic step involving Rubottom oxidation of a silyl enol ether isoleucine intermediate to form δ-OH substituted keto-isoleucine intermediates (see also Scheme 2): .

[0025] In another aspect of the present disclosure is a compound-linker construct comprising an amatoxin analog and a linker for conjugating the construct to a target-binding moiety.

[0026] In another aspect of the present disclosure, the target-binding moiety of the conjugate is an antibody, an antigen-binding fragment thereof or an antibody-like protein.

[0027] In another aspect of the present disclosure, is the use of an effective amount of the compound or conjugate for treatment of a disease associated with cells presenting a target in a subject, wherein the target-binding moiety is specific for the target.

[0028] In another aspect of the present disclosure, is the use of an effective amount of the compound or conjugate for treatment of cancer in a subject.

[0029] Other features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating embodiments of the disclosure, are given by way of illustration only and the scope of the claims should not be limited by these embodiments, but should rather be given the broadest interpretation consistent with the description as a whole. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] The embodiments of the disclosure will now be described in greater detail with reference to the attached drawings, in which:

[0031] FIG.1 shows a nuclear magnetic resonance spectroscopy (NMR) COSY spectrum of ((3S,4R,5R)-5-(hydroxymethyl)-4-methyl-2-oxotetrahydrofuran-3-yl)carbamate (1H,1H) 400 MHz, CD2Cl2(upper) and a zoomed in image of the COSY spectrum (lower).

[0032] FIG. 2 shows a NMR NOESY spectrum of ((3S,4R,5R)-5-(hydroxymethyl)-4- methyl-2-oxotetrahydrofuran-3-yl)carbamate (1H,1H) 400 MHz, CD2Cl2(upper) and a zoomed in image of the NOESY spectrum (lower).

[0033] FIG. 3 shows the results of a 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) viability assay on human embryonic kidney (HEK) 293 cells for (2S,3R,4S)-Mono-OH-Ama (A1), (2S,3R,4R)-F-OH-Ama (A2), (2S,3R,4S)-F-OH- Ama (A3) and (2S,3R,4R)-Azido-OH-Ama (A4) in comparison to α-amanitin.

[0034] FIG.4 shows the results of an MTT viability assay on Chinese hamster ovary (CHO) cells for A1, A2, A3 and A4 in comparison to α-amanitin.

[0035] FIG.5 shows the results of an MTT viability assay on HeLa cells for A1, A2, A3 and A4 in comparison to α-amanitin.

[0036] FIG.6 shows the results of an MTT viability assay on HepG2 cells for A1, A2, A3 and A4 in comparison to α-amanitin.

[0037] FIG. 7 shows the results of an MTT viability assay on HEK 293 cells for (2S,3R,4R)-tBu-S-S-OH-Ama (A6) in comparison to α-amanitin.

[0038] FIG. 8 shows the results of an MTT viability assay on CHO cells for A6 in comparison to α-amanitin.

[0039] FIG. 9 shows the results of an MTT viability assay on HeLa cells for A6 in comparison to α-amanitin.

[0040] FIG.10 shows the results of an MTT viability assay on HepG2 cells for A6 in comparison to α-amanitin.

[0041] FIG. 11 shows the results of an MTT viability assay on HEK 293 cells for (2S,3R,4R)-NH2-OH-Ama (A7) in comparison to α-amanitin.

[0042] FIG.12 shows the results of an MTT viability assay on HepG2 cells for A7 and (2S,3R,4R)-epoxy-Ama (A8) in comparison to α-amanitin.

[0043] FIG.13 shows the results of an MTT viability assay on HEK 293 cells for A8 in comparison to α-amanitin.

[0044] FIG.14 shows the results of an MTT viability assay on CHO cells for A8 in comparison to α-amanitin.

[0045] FIG.15 shows the results of an MTT viability assay on HeLa cells for A7 and A8 in comparison to α-amanitin.

[0046] FIG.16 shows the results of an MTT viability assay on CHO cells for A7 in comparison to α-amanitin.

[0047] FIG.17 shows the results of an MTT viability assay on HEK 293 cells for (2S,3R,4R)- SH-OH-Ama (A9) and (2S,3R,4R)-S-S-OH-Ama (A10) in comparison to α-amanitin.

[0048] FIG.18 shows the results of an MTT viability assay on CHO cells for A9 in comparison to α-amanitin.

[0049] FIG.19 shows the results of an MTT viability assay on CHO cells for A10 in comparison to α-amanitin.

[0050] FIG.20 shows the results of an MTT viability assay on HeLa cells for A9 in comparison to α-amanitin.

[0051] FIG.21 shows the results of an MTT viability assay on HeLa cells for A10 in comparison to α-amanitin.

[0052] FIG.22 shows the results of an MTT viability assay on HepG2 cells for A10 in comparison to α-amanitin.

[0053] FIG.23 shows the results of an MTT viability assay on HepG2 cells for A9 in comparison to α-amanitin.

[0054] FIG.24 shows the results of an MTT viability assay on SK-BR-3 cells for A9 ADC in comparison to α-amanitin, A9, A10 and KadcylaTM. DETAILED DESCRIPTION I. Definitions

[0055] Unless otherwise indicated, the definitions and embodiments described in this and other sections are intended to be applicable to all embodiments and aspects of the disclosure herein described for which they would be understood to be suitable by a person skilled in the art.

[0056] As used herein, the words “comprising” (and any form thereof, such as “comprise” and “comprises”), “having” (and any form thereof, such as “have” and “has”), “including” (and any form thereof, such as “include” and “includes”) or “containing” (and any form thereof, such as “contain” and “contains”), are inclusive or open-ended and do not exclude additional, unrecited elements or process / method steps. As used herein, the word “consisting” and its derivatives are intended to be close-ended terms that specify the presence of the stated features, elements, components, groups, integers and / or steps, and also exclude the presence of other unstated features, elements, components, groups, integers and / or steps. The term “consisting essentially of”, as used herein, is intended to specify the presence of the stated features, elements, components, groups, integers, and / or steps as well as those that do not materially affect the basic and novel characteristic(s) of these features, elements, components, groups, integers and / or steps.

[0057] Terms of degree such as “substantially”, “about” and “approximately” as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least ±5% of the modified term if this deviation would not negate the meaning of the term it modifies.

[0058] As used in this disclosure, the singular forms “a”, “an” and “the” include plural references unless the content clearly dictates otherwise.

[0059] The term “and / or” as used herein means that the listed items are present, or used, individually or in combination. In effect, this term means that “at least one of” or “one or more” of the listed items is present or used.

[0060] The term “alkyl” as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkyl groups. The number of carbon atoms that are possible in the referenced alkyl group are indicated by the numerical prefix “Cn1-n2”. For example, the term C1-6alkyl means an alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.

[0061] The term “alkenyl” as used herein, whether it is used alone or as part of another group, means straight or branched chain, unsaturated alkenyl groups. The number of carbon atoms that are possible in the referenced alkenyl group are indicated by the numerical prefix “Cn1-n2”. For example, the term C2-20alkenyl means an alkenyl group having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and at least one double bond, for example 1-3, 1-2 or 1 double bond.

[0062] The term “alkynyl” as used herein, whether it is used alone or as part of another group, means straight or branched chain, unsaturated alkynyl groups. The number of carbon atoms that are possible in the referenced alkynyl group are indicated by the numerical prefix “Cn1-n2”. For example, the term C2-20alkynyl means an alkenyl group having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and at least one triple bond, for example 1-3, 1-2 or 1 triple bond.

[0063] The term “cycloalkyl” as used herein, whether it is used alone or as part of another group, means a mono- or bicyclic, saturated cycloalkyl group. The number of carbon atoms that are possible in the referenced cycloalkyl group are indicated by the numerical prefix “Cn1-n2”. For example, the term C3-10cycloalkyl means a cycloalkyl group having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. When a cycloalkyl group contains more than one cyclic structure or rings, the cyclic structures may be fused, bridged, spiro connected or linked by a single bond. The term “fused” as used herein in reference to a first cyclic structure being “fused” with a second cyclic structure means the first cyclic structure and the second cyclic structure share at least two adjacent atoms therebetween. The term “bridged” as used herein in reference to a first cyclic structure being “bridged” with a second cyclic structure means the first cyclic structure and the second cyclic structure share at least two non-adjacent atoms therebetween. The term “spiro-connected” in reference to a first cyclic structure being “spiro connected” with a second cyclic structure means the first cyclic structure and the second cyclic structure share one atom therebetween.

[0064] The term “aryl” as used herein, whether it is used alone or as part of another group, refers to cyclic groups that contain at least one aromatic ring. The number of carbon atoms that are possible in the referenced aryl group are optionally indicated by thenumerical prefix “Cn1-n2”. For example, the term C6-30aryl means an aryl group having 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 carbon atoms. In an embodiment, the aryl group contains from 6, 9, 10 or 14 carbon atoms, such as phenyl, naphthyl, indanyl or anthracenyl.

[0065] The term “heterocycloalkyl” as used herein, whether it is used alone or as part of another group, refers to a non-aromatic, ring-containing group having one or more multivalent heteroatoms, for example, independently selected from O, S and Se, as a part of the ring structure and including at least 3 and up to 20 atoms in the ring(s). Heterocycloalkyl groups are either saturated or unsaturated (i.e. contain one or more double bonds) and may contain more than one ring.

[0066] The term “heteroaryl” as used herein, whether it is used alone or as part of another group, refers to an aromatic, ring-containing group having one or more multivalent heteroatoms, for example, independently selected from O, S, Se and N, as a part of the ring structure and including at least 5 and up to 20 atoms in the ring(s). Heteroaryl groups may contain more than one ring.

[0067] The term “halo” as used herein refers to a halogen atom and includes F, Cl and Br.

[0068] The term “available”, as used herein in reference to “available hydrogens”, “available carbon atoms”, “available atoms” and the like refers to atoms that would be known to a person skilled in the art to be capable of modification and / or replacement by another atom or substituent.

[0069] The term “replaced with its radioactive isotope” as used herein in reference to one or more available atoms in the amatoxin analogs of the present disclosure means that a non- radioactive isotope of the atom is replaced with the corresponding radioactive isotope. For example, in an embodiment, a non-radioactive isotope of hydrogen is replaced with3H (tritium). In another embodiment, a non-radioactive isotope of carbon is replaced with11C or14C. In a further embodiment, a non-radioactive isotope of iodine is replaced with123I,125I or131I. In another embodiment, a non-radioactive isotope of sulfur is replaced with35S. It will be appreciated by a person skilled in the art that depending, for example, on the radioactive isotope, such radiolabelled compounds may, for example, be useful as radiopharmaceuticals for treatment and / or diagnostic applications. The selection of a suitable radioactive isotope and methods for the preparation of radiolabelled compounds can be made by a person skilled in the art.

[0070] The terms “protective group” or “protecting group” or “PG” or the like as used herein refer to a chemical moiety which protects or masks a reactive portion of a molecule to prevent side reactions in those reactive portions of the molecule, while manipulating orreacting a different portion of the molecule. After the manipulation or reaction is complete, the protecting group is removed under conditions that do not degrade or decompose the remaining portions of the molecule. The selection of a suitable protecting group can be made by a person skilled in the art. Many conventional protecting groups are known in the art, for example as described in “Protective Groups in Organic Chemistry” McOmie, J.F.W. Ed., Plenum Press, 1973, in Greene, T.W. and Wuts, P.G.M., “Greene’s Protective Groups in Organic Synthesis”, John Wiley & Sons, 4th Edition, 2006 and in Kocienski, P. Protecting Groups, 3rd Edition, 2003, Georg Thieme Verlag (The Americas). A person skilled in the art would readily appreciate that the selection of a suitable protecting group may depend, for example, on the group to be protected or masked and / or the manipulation or reaction to be carried out and could select a suitable group accordingly having regard to the present disclosure. Examples of suitable protecting groups include, but are not limited to Boc, Ac, Ts, Ms, silyl ethers such as TMS, TBS, TBDMS, TBDPS, Tf, Ns, Bn, Fmoc, dimethoxytrityl, methoxyethoxymethyl ether, methoxymethyl ether, pivaloyl, p-methoxyphenyl p-methyoxybenzyl ether, tetrahydropyranyl, trityl, ethoxyethyl ethers, carbobenzyloxy, benzoyl and the like.

[0071] The term “subject” as used herein includes all members of the animal kingdom including mammals. In an embodiment, the subject is a human.

[0072] The term “pharmaceutically acceptable” as used herein means compatible with the treatment of subjects, for example, mammals such as humans.

[0073] The term “pharmaceutically acceptable salt” as used herein means either an acid addition salt or a base addition salt that is compatible with the treatment of subjects.

[0074] An “acid addition salt that is compatible with the treatment of subjects” is any suitable non-toxic organic or inorganic salt of any basic compound. Basic compounds that form an acid addition salt include, for example, compounds comprising an amine group susceptible to protonation. Illustrative inorganic acids which form suitable salts include but are not limited to hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as but not limited to sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that may form suitable salts include but are not limited to mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as but not limited to p-toluene sulfonic and methanesulfonic acids. The selection of a suitable salt can be made by a personskilled in the art. The formation of a desired acid addition salt is, for example, achieved using standard techniques. For example, in an embodiment, the neutral compound is treated with the desired acid in a suitable solvent and the salt which is thereby formed then isolated by filtration, extraction and / or any other suitable method.

[0075] A “base addition salt that is compatible with the treatment of subjects” is any suitable nontoxic inorganic or organic salt of any acidic compound. Acidic compounds that form a base addition salt include, for example, compounds comprising a sulfonic acid group. Inorganic bases that may form suitable salts include, without limitation, lithium, sodium, potassium, calcium, magnesium or barium hydroxide. Organic bases that may form suitable salts include, without limitation, aliphatic, alicyclic or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of a suitable salt can be made by a person skilled in the art. The formation of a desired base addition salt is, for example, achieved using standard techniques. For example, in an embodiment, the neutral compound is treated with the desired base in a suitable solvent and the salt which is thereby formed then isolated by filtration, extraction and / or any other suitable method.

[0076] The terms “to treat”, “treating” and “treatment” as used herein and as is well understood in the art, mean an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results include but are not limited to alleviation or amelioration of one or more symptoms of a disease (e.g. cancer), diminishment of the extent of the disease, stabilization (i.e. not worsening) of the disease, delay or slowing of the progression of the disease, amelioration or palliation of the state of the disease, diminishment of the recurrence of the disease and / or remission (whether partial or total) of the disease, whether detectable or undetectable. To “treat”, “treating” and “treatment” as used herein also include prophylactic treatment of the disease. For example, in an embodiment, a subject with early-stage disease is treated to prevent progression or alternatively a subject in remission is treated to prevent recurrence.

[0077] As used herein, the term “effective amount” means an amount effective, at dosages and for periods of time necessary to achieve a desired result. For example, in the context of treating cancer, an effective amount of an amatoxin analog or conjugate of the present disclosure is an amount that, for example, reduces the cancer compared to the cancer without administration or use of the amatoxin analog or conjugate, respectively. Effective amounts may vary according to factors such as the disease state, age, sex and / orweight of the subject. The amount of a given amatoxin analogue or conjugate, as the case may be, that will correspond to such an amount will vary depending upon various factors, such as the given amatoxin analog or conjugate, the pharmaceutical formulation, the type of disease being treated, the identity of the subject being treated, and the like, but can nevertheless be routinely determined by one skilled in the art.

[0078] The term “suitable” as used herein means that the selection of the particular compound and / or conditions would depend on the specific synthetic manipulation to be performed, and / or the identity of the compound(s) to be transformed, but the selection would be well within the skill of a person skilled in the art. All synthetic method steps described herein are to be conducted under conditions sufficient to provide the product shown. A person skilled in the art would understand that all reaction conditions, including, for example, reaction solvent, reaction time, reaction temperature, reaction pressure, reactant ratio and whether or not the reaction should be performed under an anhydrous or inert atmosphere, can be varied to optimize the yield of the desired product and it is within their skill to do so. II. DHIle and Amatoxin analogs, Amatoxin-Linker Constructs and Conjugates

[0079] The present disclosure includes an amatoxin analog comprising a DHIle residue with a sidechain of the formula: , wherein R1is H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2; and R2is H, OR ', NHR ', SR ' or halo; or R1and R2, together with the carbon atoms to which they are attached, form epoxy; each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl,or a pharmaceutically acceptable salt thereof, provided that when R1is H or OH, R2is other than H or OH, and when R2is H or OH, R1is other than H or OH; and wherein in the amatoxin analog or the pharmaceutically acceptable salt thereof, one or more available hydrogens is / are optionally replaced with deuterium and / or one or more available hydrogens is / are optionally replaced with fluorine and / or one or more available atoms is / are optionally replaced with its radioactive isotope.

[0080] The amatoxin can be any suitable amatoxin. The term “amatoxin” as used herein includes all cyclic peptides composed of 8 amino acids as isolated from the genus Amanita and described, for example, by Wieland, T. and Faulstich, H. in CRC Critical Reviews in Biochemistry 1978, 5 (3), 185-260 as well as all suitable chemical derivatives, semisynthetic analogs and synthetic analogs thereof built from building blocks according to the master structure of the natural compounds (cyclic, 8 amino acids). The term “amatoxin” as used herein also includes all suitable synthetic or semisynthetic analogs of amatoxins containing non- hydroxylated amino acids instead of the hydroxylated amino acids and / or amino acids comprising beta-alkyl groups such as beta-methyl groups and / or in which the sulfoxide moiety is replaced by a sulfone, or thioether, or by atoms different from sulfur, e.g., a carbon atom as in a carbanalog of amanitin. In an embodiment, the amatoxin has a functional group (e.g. a carboxylic group, an amino group, a hydroxy group, a thiol, a thiol-capturing group, an alkynyl group and / or an -N3group) that can be reacted with a complementary functional group on a linker and / or a target-binding moiety as defined herein. In an embodiment of the present disclosure, the amatoxin is an α-amanitin, α-amanitin, ^-amanitin, ^-amanitin, amanullin, amanullinic acid, amanin, amaninamide, ^-amanin or ^-amaninamide or a derivative thereof.

[0081] In an embodiment, the amatoxin analog is a compound of Formula I: , wherein A is S, S(O), SO2, Se, Se(O) or SeO2;R1is H, OR ', NR 'R2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2; and R2is H, OR ', NHR ', SR ' or halo; or R1and R2, together with the carbon atoms to which they are attached, form epoxy; R3is OR ', NH(OR '), NH-NHR ' or N(R ')2; R4is OR ', NH(OR '), NH-NHR ' or N(R ')2; R5is H or OH; n is an integer from 0 to 4; and each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, or a pharmaceutically acceptable salt thereof; provided that when R1is H or OH, R2is other than H or OH, and when R2is H or OH, R1is other than H or OH; and wherein in the compound of Formula I or the pharmaceutically acceptable salt thereof, one or more available hydrogens is / are optionally replaced with deuterium and / or one or more available hydrogens is / are optionally replaced with fluorine and / or one or more available atoms is / are optionally replaced with its radioactive isotope.

[0082] In an embodiment, the amatoxin analog of Formula I has the following stereochemistry: .

[0083] In an embodiment, R4is OR ' or N(R ')2. In another embodiment, R4is OR ' or N(R ')2, wherein R ' is H. In a further embodiment, R4is NH2. In another embodiment, R4is -N(R ')2, wherein one R ' is H and the other R ' is C1-20alkyl substituted with -N3. In a further embodiment, R4is -N(R ')2, wherein one R ' is H and the other R ' is C1-6alkyl substituted with -N3. In another embodiment, R4is -N(H)CH2CH2N3.

[0084] In an embodiment, R5is H. In another embodiment, R5is OH.

[0085] In an embodiment, R2is H or OR '. In another embodiment, R2is OH. In an embodiment, R2is -OH (S). In another embodiment, R2is -OH (R).

[0086] In an embodiment, n is an integer from 0 to 3. In another embodiment, n is 0, 1 or 2. In another embodiment, n is 0 or 1. In an embodiment, n is 0. In another embodiment, n is 1.

[0087] In an embodiment, each R3is independently OR '. In another embodiment, R3is OH. In a further embodiment, R3is 4-OH, 5-OH, 6-OH or 7-OH. In an embodiment, R3is 5-OH.

[0088] In an embodiment, A is S, (R)-S(O), Se or (R)-Se(O). In an embodiment, A is S or (R)-S(O). In another embodiment, A is S. In a further embodiment, A is (R)-S(O).

[0089] In an embodiment, R1is selected from -H, -OH, -F, -Cl, -Br, -N3, -S-S-tBu, - SH, -NH2, epoxy, imidazole, -CN, -SOR, -ONH2, -NHOH, -SO2R, -SeR, and -NHNH2(where R is selected from H, Me, Et, iPr or another optionally substituted C1-10alkyl group).

[0090] In an embodiment, R1is H, OR ', N(R ')2, SR ', halo, -N3, or -S-S-R '. In another embodiment, R1is H, OR ', N(R ')2, SR ', halo, -N3, or -S-S-R '. In another embodiment, R1is H, N(R ')2, SR ', halo, -N3, or -S-S-R ', wherein R ' is H or C1-6alkyl, or R1and R2, together with the carbon atoms to which they are attached, form epoxy. In a further embodiment, R1is F, Br, -N3, -S-S-tBu, NH2, SH or -S-S-CH(CH3)CH(CH3)2. In another embodiment, R1is F, Br, -N3, -S-S-tBu, or NH2. In an embodiment, R1is F. In another embodiment, R1is Br. In an embodiment, R1is -N3. In another embodiment, R1is -S-S-tBu. In a further embodiment, R1is NH2. In an embodiment, R1and R2, together with the carbon atoms to which they are attached, form epoxy. In another embodiment, R1is SH. In a further embodiment, R1is -S-S-CH(CH3)CH(CH3)2.

[0091] In an embodiment, R ' is H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl andheteroaryl is unsubstituted. In another embodiment, R ' is H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3 and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl. In a further embodiment, each R ' is independently H or C1-20alkyl. In an embodiment, R ' is C1-6alkyl. In another embodiment, R ' is H.

[0092] In an embodiment, the amatoxin analog is:(A9); or (A10) or a pharmaceutically acceptable salt thereof.

[0093] In an embodiment, the amatoxin analog is: (A1).

[0094] In an embodiment, the amatoxin analog is: (A2).

[0095] In an embodiment, the amatoxin analog is: (A3).

[0096] In an embodiment, the amatoxin analog is: (A4).

[0097] In an embodiment, the amatoxin analog is: (A5).

[0098] In an embodiment, the amatoxin analog is: (A6).

[0099] In an embodiment, the amatoxin analog is: (A7).

[0100] In an embodiment, the amatoxin analog is: (A8).

[0101] In an embodiment, the amatoxin analog is: (A9).

[0102] In an embodiment, the amatoxin analog is: (A10).

[0103] In an embodiment, the amatoxin analog is not in the form of a salt. In an alternative embodiment, the amatoxin analog is in the form of a pharmaceutically acceptable salt.

[0104] The amatoxin analogs of the present disclosure such as the compounds of Formula I, and salts thereof, as described herein may, for example, be coupled to a linker to provide an amatoxin-linker construct that may, for example, be used in the manufacture of conjugates which may, for example, be useful in the treatment of diseases such as cancer.

[0105] Accordingly, the present disclosure also includes an amatoxin-linker construct comprising an amatoxin analog as described herein (which may include pharmaceutically acceptable salts thereof) coupled to a linker, wherein the linker comprises a reactive group R6for conjugating the amatoxin-linker construct to a target-binding moiety.

[0106] The amatoxin analogs of the present disclosure are coupled to the linker in any suitable configuration, the selection of which can be made by a person skilled in the art. For example, the location of the coupling may depend, for example, on the identity of the amatoxin analog and / or the linker. In an embodiment, the linker is coupled to the amatoxin analog or the salt thereof at a site indicated by R1, R2, R3, R4and / or R5in an amatoxin analog as described herein. In another embodiment, the linker is coupled to the amatoxin analog or the salt thereof through a moiety obtained from the reaction of R1, R2, R3, R4and / or R5in an amatoxin analog as described herein with a complementary functional group on the linker.

[0107] The linker can be any suitable linker. For example, it will be appreciated by a person skilled in the art that amatoxins are relatively non-toxic when coupled to a biomolecule carrier such as a target-binding moiety, and advantageously only exert their cytotoxic activity after internalization in the target cells. Accordingly, a conjugate comprising the target-binding moiety conjugated to the compound coupled to the linker is advantageously substantially stable in the plasma after administration and a suitable linker may desirably allow, for example, for substantially releasing the compound subsequent to internalization in the target cells. Many linkers suitable for use in amatoxin-linker constructs are known in the art, for example, suitable linkers for some embodiments of the present disclosure are described in PCT Application Publication No. WO / 2023 / 097407 entitled “Modified Amatoxins and Uses Thereof”.

[0108] In an embodiment, the linker is stable linker. The term “stable linker” as used herein refers to a linker that typically releases the compound after the target-binding moiety to which it is conjugated is degraded intracellularly, for example, in the lysosomes. In otherwords, the linker is substantially stable in an intracellular reducing environment and in the presence of enzymes such as lysosomal peptidases (e.g. Cathepsin B). In an embodiment, the stable linker is devoid of an enzyme-cleavable structure (e.g. a dipeptide sequence cleavable by Cathepsin B) and / or a disulfide group. In another embodiment, the stable linker comprises an –[CH2-X1-CH2]s–CH2– moiety, wherein X1is O, CH2or S, and s is an integer from 1 to 8.

[0109] In another embodiment of the present disclosure, the linker is a cleavable linker. The term “cleavable linker” as used herein refers to a linker that is cleavable by an enzyme and / or in a reducing environment. In an embodiment of the present disclosure, the cleavable linker is cleavable by an intracellular protease. In another embodiment of the present disclosure, the linker is cleavable by at least one agent selected from the group consisting of cysteine protease, metalloproteinase, serine protease, threonine protease, aspartic protease, glycosidase, phosphodiesterase, and reductase. Such linkers may, for example, comprise a peptide motif cleavable by such an enzyme. In another embodiment of the present disclosure, the linker comprises a motif selected from the group consisting of: Val-Ala, Val-Cit, Val- Lys, Val-Arg, Phe-Lys-Gly-Pro-Leu-Gly, Ala-Ala-Pro-Val, β-glucuronide and β-galactoside.

[0110] In an embodiment, the linker is a stable linker, but the linker is coupled to the amatoxin analog or the salt thereof through a moiety cleavable by an enzyme and / or in a reducing environment. In another embodiment, the linker is coupled to the amatoxin analog or the salt thereof through a moiety cleavable in a reducing environment. In another embodiment, the moiety cleavable in a reducing environment is a disulfide.

[0111] In an embodiment, the linker further comprises a self-immolating moiety. The term “self-immolating moiety” as used herein, refers to a moiety, which, after enzymatic cleavage of the linker, spontaneously cleaves from the remainder of the amatoxin-linker construct, thereby releasing the compound. In an embodiment, the self-immolating moiety is a p-aminobenzyl alcohol (PAB) moiety. In another embodiment, the PAB is conjugated to a peptide (e.g. a dipeptide) portion of the linker via the aromatic amine group of the PAB. In another embodiment, the PAB is conjugated to the compound via a carbamate group coupled to a primary or secondary amine or in an alternative embodiment, the PAB is coupled directly to the amatoxin analogue.

[0112] The reactive group R6is any reactive group suitable for conjugating the amatoxin- linker construct to a target-binding moiety and may depend, for example, on the identity of the target-binding moiety and / or a complimentary reactive group thereon.

[0113] In an embodiment of the present disclosure, R6is selected from: ; ; ; ; ; ; ; ; ; ; ; ; and , wherein represents the site of attachment of R6to the remainder of the linker; or R6comprises an azide, thiol, tetrazine, trans-cyclooctene or acrylamide functional group.

[0114] In an embodiment, R6is .

[0115] In an embodiment, R1and / or R4comprise an N3moiety, the complementary functional group on the linker is an alkyne, and the linker is coupled to the amatoxin analog or the salt thereof through a 1,2,3-triazole. In an embodiment, R4comprises an N3moiety, the complementary functional group on the linker is an alkyne, and the linker is coupled to the amatoxin analog or the salt thereof through a 1,2,3-triazole. In another embodiment, R4comprises -CH2CH2N3, the complementary functional group on the linker is an alkyne, and the linker is coupled to the amatoxin analog or the salt thereof through a 1,2,3-triazole.

[0116] In another embodiment, R1comprises an SH moiety, the complementary functional group comprises an orthopyridyl disulfide, and the linker is coupled to the amatoxin analog or the salt thereof through a disulfide.

[0117] The present disclosure also includes a conjugate comprising a target-binding moiety conjugated to an amatoxin analog or an amatoxin-linker construct as described herein.

[0118] In an embodiment, the conjugate comprises the target-binding moiety conjugated to the amatoxin analog. In another embodiment, the conjugate comprises the target-binding moiety conjugated to the amatoxin-linker construct.

[0119] The term “target-binding moiety” as used herein refers to any suitable moiety that can specifically bind to a target molecule (e.g. protein) or epitope. In an embodiment, the target-binding moiety is a peptide, an oligonucleotide, a lipid, a lipid carrier, a nanoparticle or combinations thereof. In another embodiment, the target-binding moiety is an antibody, an antigen-binding fragment thereof, an antibody-like protein, an aptamer, a vitamin, an oligonucleotide, an affibody, a minibody, a lipid, a lipid carrier, a nanoparticle or combinations thereof. In another embodiment, the target-binding moiety is an antibody, an antigen-binding fragment thereof, an antibody-like protein, an aptamer, a vitamin, an oligonucleotide, an affibody, a minibody, a lipid, a lipid carrier or a nanoparticle. In a further embodiment, the target-binding moiety is an antibody, antigen-binding fragment thereof or an antibody-like protein. In a further embodiment, the target-binding moiety is an antibody. In an embodiment, the conjugate has a drug-to-target-binding moiety ratio e.g., a drug-to- antibody ratio (DAR) of about 0.1 to about 10, about 0.5 to about 5 or about 1 to about 3. In another embodiment, the conjugate has a drug-to-target-binding moiety ratio e.g., a drug-to- antibody ratio (DAR) of about 2. The term “antigen-binding fragment thereof” as used herein means that the fragment of the antibody comprises at least a functional antigen-binding domain. The term “antibody-like protein” as used herein refers to a protein that is not strictly an antibody but has the capability of binding to a target molecule (e.g. protein) or epitope. The “antibody-like protein” is a protein that has been engineered (e.g. by mutagenesis of Ig loops) to specifically bind to the target molecule. Typically, such an antibody-like protein comprises at least one variable peptide loop attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the antibody-like protein to levels comparable to that of an antibody. The length of the variable peptide loop typically consists of 10 to 20 amino acids. The scaffold protein may be any protein having good solubility properties. In an embodiment, the scaffold protein is a small globular protein. The scaffold of antibody-like proteins can be based on, for example, without limitation, affilin proteins, affibodies, anti-calins, lipocalins, ubiquitin, leucine-rich repeat proteins, anddesigned ankyrin repeat proteins (see, for example: Binz et al., “Engineering novel binding proteins from nonimmunoglobulin domains” Nat Biotechnol. 2005, 23:10, 1257-68). The antibody or antigen-binding fragment thereof can be from any suitable immunoglobulin type (e.g. IgG, IgE, IgM, IgD, IgA and / or IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and / or IgA2) or subclass. Suitable antibodies and / or antigen-binding fragments thereof may include but are not limited to polyclonal, monoclonal, monovalent, bispecific, heteroconjugate, multispecific, human, humanized (e.g. CDR-grafted), deimmunized, and / or chimeric antibodies, single chain antibodies (e.g. scFv), Fab fragments, F(ab')2fragments, fragments produced by a Fab expression library, diabodies or tetrabodies, nanobodies, anti-idiotypic (anti-Id) antibodies (including, but not limited to anti-Id antibodies to antibodies of the present disclosure), and epitope-binding fragments of any of the above.

[0120] In an embodiment, the antigen-binding fragments are human antigen-binding antibody fragments and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single- chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (dsFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable domain(s) alone or in combination with the entirety or a portion of the following: hinge region, CL, CH1, CH2, and CH3 domains. Also included are antigen-binding fragments also comprising any combination of variable domain(s) with a hinge region, CL, CH1, CH2, and CH3 domains. The antibody, antigen- binding fragment thereof or antibody-like protein may be from any animal origin including birds and mammals. For example, in an embodiment, the antibody, antigen-binding fragment thereof or antibody-like protein is from human, rodent (e.g. mouse, rat, guinea pig, or rabbit), chicken, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog origin. In another embodiment, the antibody, antigen-binding fragment thereof or antibody-like protein is of human or murine origin. The term “human” as used herein in reference to antibodies includes antibodies having the amino acid sequence of a human immunoglobulin and also includes antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described for example in U.S. Patent No.5,939,598.

[0121] The term “specifically bind” as used herein in reference to a target-binding moiety specifically binding to a target molecule or epitope means, for example, that it has a dissociation constant KDto the target molecule or epitope of at most about 100 ^M. In anembodiment, KD is about 100 ^M or lower, about 50 ^M or lower, about 30 ^M or lower, about 20 ^M or lower, about 10 ^M or lower, about 5 ^M or lower, about 1 ^M or lower, about 900 nM or lower, about 800 nM or lower, about 700 nM or lower, about 600 nM or lower, about 500 nM or lower, about 400 nM or lower, about 300 nM or lower, about 200 nM or lower, about 100 nM or lower, about 90 nM or lower, about 80 nM or lower, about 70 nM or lower, about 60 nM or lower, about 50 nM or lower, about 40 nM or lower, about 30 nM or lower, about 20 nM or lower or about 10 nM or lower, about 1 nM or lower, about 900 pM or lower, about 800 pM or lower, about 700 pM or lower, about 600 pM or lower, about 500 pM or lower, about 400 pM or lower, about 300 pM or lower, about 200 pM or lower, about 100 pM or lower, about 90 pM or lower, about 80 pM or lower, about 70 pM or lower, about 60 pM or lower, about 50 pM or lower, about 40 pM or lower, about 30 pM or lower, about 20 pM or lower or about 10 pM or lower.

[0122] The terms “target molecule” and “target epitope” as used herein may refer to an antigen and an epitope of an antigen, respectively, that is specifically bound by a target- binding moiety such as an antibody, antigen-binding fragment thereof or antibody-like protein. The term “epitope” as used herein, also sometimes referred to in the art as an “antigenic determinant”, refers to a molecular structure to which, in the context of an adaptive immune response, antibodies or T cell receptors are directed and / or generated, and / or which can elicit a specific immune response. In the context of antibodies or antigen-binding fragments thereof, the term “epitope” as used herein relates to the specific molecular structure on the antigen to which the antigen-recognition site or paratop of the antibody or antigen- binding fragment thereof, binds. In an embodiment, the target molecule or target epitope is associated with cancer, non-cancerous neoplasms, an autoimmune disease, an inflammatory disease or a viral infection. In an embodiment, the target molecule or target epitope is associated with cancer, an autoimmune disease, or a viral infection. In an embodiment, the target molecule or epitope is associated with cancer. In another embodiment, the target molecule or epitope associated with cancer or non-cancerous neoplasms is present on the surface of one or more tumor cell types or tumor-associated cells in an increased concentration and / or in a different steric configuration as compared to the surface of non- tumor cells. In an embodiment, the target molecule or epitope associated with cancer is an epitope of human epidermal growth receptor 2 (HER2), prostate-specific membrane antigen (PSMA), CD20, CD269, sialyl LewisX, HER-2 / neu or epithelial cell adhesion molecule(EpCAM). In a further embodiment, the target molecule or epitope associated with cancer is an epitope of human epidermal growth receptor 2 (HER2). In another embodiment, the target- binding moiety is an anti-HER2 antibody. In another embodiment, the anti-HER2 antibody is trastuzumab. In an embodiment, the target molecule or target epitope is associated with autoimmune disease. In another embodiment, the target molecule or epitope associated with autoimmune disease is preferentially expressed on cells involved in an autoimmune disease. In an embodiment, the target molecule or target epitope is associated with a viral infection. In another embodiment, the target molecule or epitope associated with a viral infection is preferentially expressed on cells involved in a viral infection.

[0123] In an embodiment, the conjugate comprises the amatoxin-linker construct, the target-binding moiety comprises an engineered acceptor residue, R6is a reactive group to a moiety comprised in the engineered acceptor residue, and the amatoxin-linker construct is conjugated to the target-binding moiety via a moiety resulting from the reaction of the moiety comprised in the engineered acceptor residue with R6. The term “engineered acceptor residue” as used herein refers to a residue that is introduced into a peptide sequence of a suitable target-binding moiety that is generally not present in the native peptide sequence of the target-binding moiety. Such residues are available for reaction with R6but desirably do not substantially affect, for example, immunoglobulin folding, antibody assembly, antigen binding and / or Fc domain effector functions. In an embodiment, the engineered acceptor residue is an engineered cystine residue and R6is a thiol-reactive group. The term “engineered cysteine residue” as used herein refers to a cysteine residue that is introduced into the peptide sequence of a suitable target-binding moiety that is generally not present in the native peptide sequence of the target-binding moiety. Such cysteine residues are available for conjugation but desirably do not substantially affect, for example, immunoglobulin folding, antibody assembly, antigen binding and / or Fc domain effector functions. For example, the engineered cysteine residue can take the place of the amino acid that naturally occurs at a given position in the peptide sequence; i.e. in an embodiment of the present disclosure, the engineered cysteine residue is a cysteine substitution. Engineered cysteine residues can be introduced into the peptide sequence of the target-binding moiety through suitable techniques such as site-directed mutagenesis, the selection of which can be made by a person skilled in the art. In an embodiment, the target-binding moiety comprises one engineered cysteine residue. In another embodiment, the target-binding moiety comprises greater than one engineered cysteine residue, for example, two engineered cysteine residues. For example, antibodieswherein the amino acid aspartic acid at position 265 has been exchanged to cysteine (D265) contain two introduced cysteines at each chain of the Fc region, which can serve as conjugation sites for the amatoxin-linker construct to produce a conjugate with DAR=2.

[0124] In an embodiment, the engineered cysteine residue is selected from the group consisting of heavy chain 118Cys, heavy chain 239Cys, and heavy chain 265Cys. In another embodiment, the engineered cysteine residue is heavy chain 265Cys.

[0125] In an embodiment, the target-binding moiety comprises a biorthogonal functional group, R6is a complementary biorthogonal functional group, and the amatoxin-linker construct is conjugated to the target-binding moiety via a moiety resulting from the reaction of the biorthogonal functional group on the target-binding moiety with R6. The term “biorthogonal” as used herein refers to a chemical reaction capable of occurring inside of a living system without interfering with native biochemical processes. Biorthogonal reactions are well known in the art and include but are not limited to reaction between an azide and a soft nucleophile such as a phosphine; reaction between an azide and a suitable acetylene, and 1,3-dipolar cycloaddition between an azide and a suitable cyclooctyne or azacyclooctyne (copper-free click chemistry).

[0126] In an embodiment, the target-binding moiety comprises a primary amino group, R6is a reactive group to the primary amino group, and the amatoxin-linker construct is conjugated to the target-binding moiety via a moiety resulting from the reaction of the primary amino group with R6. In another embodiment, the primary amino group is a lysine side chain. III. Uses

[0127] The present disclosure also includes a composition comprising an amatoxin analog or conjugate of the present disclosure and a carrier. In an embodiment, the composition comprises the amatoxin analog of the present disclosure and the carrier. In another embodiment, the composition comprises the conjugate of the present disclosure and the carrier. The amatoxin analogs and / or conjugates of the present disclosure are optionally formulated into pharmaceutical compositions for administration or use in a biologically compatible form, for example, a form suitable for administration to or for use in subjects in vivo. Accordingly, the present disclosure also includes a pharmaceutical composition comprising an amatoxin analog or conjugate of the present disclosure and a pharmaceutically acceptable carrier. In an embodiment, the pharmaceutical composition comprises the amatoxin analog of the present disclosure and the pharmaceutically acceptable carrier. Inanother embodiment, the pharmaceutical composition comprises the conjugate of the present disclosure and the pharmaceutically acceptable carrier.

[0128] The amatoxin analog or conjugate of the present disclosure can be administered to a subject or used in a variety of forms depending on the selected route of administration or use, as will be understood by a person skilled in the art. For example, the amatoxin analog or conjugate of the present disclosure is suitably administered to the subject or for use parenterally; i.e. taken into the body or administered or used in a manner other than through the gastrointestinal tract. In an embodiment, the amatoxin analog or conjugate of the present disclosure is administered or for use as an injectable or infusion. Injectables can be formulated in the form of ampules and / or as a ready-for-use injectable such as a ready-to-use syringe, a single-use syringe and / or in a puncturable flask for multiple withdrawal. In another embodiment, the injectable is administered or for use in the form of a subcutaneous (s.c.), intramuscular (i.m.), intravenous (i.v.) or intracutaneous (i.c.) injection. In an embodiment, the infusion is in the form of an isotonic solution, fatty emulsion, liposomal formulation or micro-emulsion. A person skilled in the art would know how to prepare suitable formulations. In some embodiments, the injectable or infusion formulation is in the form of a concentrate which can be dissolved or dispersed with aqueous isotonic diluents. Injectable formulations can also be administered or for use in the form of a permanent infusion e.g. via a mini-pump.

[0129] In some embodiments, the parenteral formulation further comprises albumin, plasma, expander, surface-active substances, organic diluents, pH-influencing substances, complexing substances, polymeric substances or combinations thereof, for example to influence the adsorption of the amatoxin analog or conjugate of the present disclosure to proteins or polymers and / or to reduce the adsorption of the amatoxin analog or conjugate of the present disclosure to materials like injection instruments or packaging-materials, for example, plastic or glass.

[0130] In some embodiments, adjuvants and carriers in the pharmaceutical compositions formulated as parenterals are one or more of aqua sterilisata (sterilized water), pH value influencing substances (for example, suitable organic or inorganic acids or bases and salts thereof or suitable combinations thereof), buffering substances for adjusting pH values, substances for isotonization (for example, sodium chloride, sodium hydrogen carbonate, glucose, fructose or combinations thereof), surfactants (for example, partial esters of fatty acids of polyoxyethylene sorbitans such as a TweenTMsurfactant or fatty acid esters of polyoxyethylenes such as a CremophorTMsurfactant or combinations thereof), fatty oils (forexample, soybean oil, castor oil or combinations thereof), synthetic esters of fatty acids (for example, ethyl oleate, isopropyl myristate or combinations thereof), polymeric adjuvants (for example, gelatine, dextran, polyvinylpyrrolidone or combinations thereof), additives which increase the solubility of organic solvents (for example, propylene glycol, ethanol, N,N- dimethylacetamide or combinations thereof), complex forming substances (for example, citrate, urea or combinations thereof), preservatives (for example, benzoic acid hydroxypropyl ester, benzoic acid methyl ester, benzyl alcohol or combinations thereof), antioxidants (for example, sodium sulfite) and stabilizers (for example, ethylenediaminetetraacetic acid, EDTA).

[0131] In another embodiment, the amatoxin analog or conjugate is orally administered or used, for example, with an inert diluent or with an assimilable edible carrier, or enclosed in hard- or soft-shell gelatin capsules, or compressed into tablets, or incorporated directly with the food of the diet. In an embodiment, for oral therapeutic administration or use, the amatoxin analog or conjugate is incorporated with excipient and administered or used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Oral dosage forms also include modified release, for example immediate release and timed-release, formulations. Examples of modified-release formulations include, for example, sustained-release (SR), extended-release (ER, XR, or XL), time-release or timed-release, controlled-release (CR), or continuous-release (CR or Contin), employed, for example, in the form of a coated tablet, an osmotic delivery device, a coated capsule, a microencapsulated microsphere, an agglomerated particle, e.g., as molecular sieving type particles, or, a fine hollow permeable fiber bundle, or chopped hollow permeable fibers, agglomerated or held in a fibrous packet. Timed-release compositions can be formulated, e.g. liposomes or those wherein the amatoxin analog or conjugate is protected with differentially degradable coatings, such as by microencapsulation, multiple coatings, etc.

[0132] The present disclosure also includes all uses for the amatoxin analogs, amatoxin- linker constructs and conjugates of the present disclosure, including, for example, use in therapeutic methods, diagnostic assays and as research tools whether alone or in combination with another active pharmaceutical ingredient.

[0133] The synthesis and biochemical evaluation of new amatoxin analogs comprising modifications of the DHIle residue is disclosed herein. Such amatoxin analogs and conjugates of the present disclosure may be useful as medicaments. Accordingly, the present disclosure also includes an amatoxin analog or conjugate of the present disclosure for use as a medicament.In an embodiment, the amatoxin analog of the present disclosure is for use as a medicament. In another embodiment, the conjugate of the present disclosure is for use as a medicament.

[0134] The present disclosure also includes a method of treating a disease associated with cells presenting a target in a subject in need thereof, the method comprising administering an effective amount of an amatoxin analog or a conjugate of the present disclosure to the subject, wherein the target-binding moiety is specific for the target. The present disclosure also includes a method of treating a disease associated with cells presenting a target in a subject in need thereof, the method comprising administering an effective amount of an amatoxin analog of the present disclosure to the subject, wherein the target-binding moiety is specific for the target. The present disclosure also includes a method of treating a disease associated with cells presenting a target in a subject in need thereof, the method comprising administering an effective amount of a conjugate of the present disclosure to the subject, wherein the target-binding moiety is specific for the target.

[0135] The present disclosure also includes a use of an amatoxin analog or a conjugate of the present disclosure for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target. The present disclosure also includes a use of an amatoxin analog of the present disclosure for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target- binding moiety is specific for the target. The present disclosure also includes a use of a conjugate of the present disclosure for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target.

[0136] The present disclosure also includes a use of an amatoxin analog or a conjugate of the present disclosure for preparation of a medicament for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target. The present disclosure also includes a use of an amatoxin analog of the present disclosure for preparation of a medicament for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target. The present disclosure also includes a use of a conjugate of the present disclosure for preparation of a medicament for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target.

[0137] The present disclosure also includes an amatoxin analog or a conjugate of the present disclosure for use to treat a disease associated with cells presenting a target in asubject, wherein the target-binding moiety is specific for the target. The present disclosure also includes an amatoxin analog of the present disclosure for use to treat a disease associated with cells presenting a target in a subject, wherein the target-binding moiety is specific for the target. The present disclosure also includes a conjugate of the present disclosure for use to treat a disease associated with cells presenting a target in a subject, wherein the target-binding moiety is specific for the target.

[0138] The term “disease associated with cells presenting a target” as used herein refers, for example, to a pathological state characterized by a cellular marker such as but not limited to a receptor and / or enzyme which can be used in a targeted fashion. In an embodiment, the disease associated with cells presenting a target is cancer, a disease associated with non- cancerous neoplasms, an autoimmune disease, an inflammatory disease or a viral infection. In another embodiment, the disease associated with cells presenting a target is cancer, an autoimmune disease or a viral infection. The term “cancer” as used herein refers to diseases caused by uncontrolled cell division and / or the ability of cells to metastasize, or to establish new growth in additional sites. In an embodiment, the cancer is a skin cancer (e.g., melanoma), a connective tissue cancer (e.g., sarcomas), an adipose cancer, a breast cancer, a head and neck cancer, a lung cancer (e.g., mesothelioma), a stomach cancer, a pancreatic cancer, an ovarian cancer, a cervical cancer, a uterine cancer, an anogenital cancer (e.g., testicular cancer), a kidney cancer, a bladder cancer, a colon cancer, a prostate cancer, a central nervous system (CNS) cancer, retinal cancer, a blood cancer, a neuroblastoma, multiple myeloma, or a lymphoid cancer (e.g., Hodgkin’s and non-Hodgkin’s lymphomas). In an embodiment, the cancer is breast cancer. In a further embodiment, the cancer is HER2- positive breast cancer. The term “autoimmune disease” can be used interchangeably with the term “autoimmune disorder” and refers to a condition in a subject characterized by cellular, tissue and / or organ injury caused by an immunologic reaction of the subject to its own cells, tissues and / or organs. The term “inflammatory disease” can be used interchangeably with the term “inflammatory disorder” and refers to a condition in a subject characterized by inflammation, such as chronic inflammation. Autoimmune disorders may or may not be associated with inflammation. Moreover, inflammation may or may not be caused by an autoimmune disorder. Thus, the skilled person would appreciate that certain disorders may e.g. be characterized as both autoimmune and inflammatory disorders. In an embodiment, the inflammatory disease is systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Autoimmune Hemolytic Anaemia (AIHA), or Sjögren’s syndrome. In an embodimentwherein the disease associated with cells presenting a target is a viral infection, the cells presenting a target are virally infected cells. In another embodiment, the viral infection is human immunodeficiency virus (HIV).

[0139] The present disclosure also includes a method of treating cancer in a subject in need thereof, the method comprising administering an effective amount of an amatoxin analog or a conjugate of the present disclosure to the subject. The present disclosure also includes a method of treating cancer in a subject in need thereof, the method comprising administering an effective amount of an amatoxin analog of the present disclosure to the subject. The present disclosure also includes a method of treating cancer in a subject in need thereof, the method comprising administering an effective amount of a conjugate of the present disclosure to the subject.

[0140] The present disclosure also includes a use of an amatoxin analog or a conjugate of the present disclosure for treatment of cancer in a subject in need thereof. The present disclosure also includes a use of an amatoxin analog of the present disclosure for treatment of cancer in a subject in need thereof. The present disclosure also includes a use of a conjugate of the present disclosure for treatment of cancer in a subject in need thereof. The present disclosure also includes a use of an amatoxin analog or a conjugate of the present disclosure for preparation of a medicament for treatment of cancer in a subject in need thereof. The present disclosure also includes a use of an amatoxin analog of the present disclosure for preparation of a medicament for treatment of cancer in a subject in need thereof. The present disclosure also includes a use of a conjugate of the present disclosure for preparation of a medicament for treatment of cancer in a subject in need thereof. The present disclosure also includes an amatoxin analog or a conjugate of the present disclosure for use to treat cancer in a subject. The present disclosure also includes an amatoxin analog of the present disclosure for use to treat cancer in a subject. The present disclosure also includes a conjugate of the present disclosure for use to treat cancer in a subject.

[0141] Treatment methods or uses comprise administering to a subject or use of an effective amount of an amatoxin analog or conjugate of the present disclosure, optionally consisting of a single administration or use, or alternatively comprising a series of administrations or uses. For example, the amatoxin analogs or conjugates of the present disclosure are administered or used at least once a week. However, in another embodiment, the amatoxin analog or conjugate is administered to the subject or for use from one time per three weeks, or one time per week to once daily for a given treatment or use. The length of the treatment period or use depends on avariety of factors, such as the severity of the disease, the age of the subject, the activity of the amatoxin analog or conjugate of the present disclosure and / or a combination thereof. It will also be appreciated by the person skilled in the art that the effective amount of an amatoxin analog or conjugate used for the treatment or use may increase or decrease over the course of a particular treatment regime or use. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration or use is required. For example, the amatoxin analog or conjugate of the present disclosure is administered or for use in an amount and for a duration suitable to treat the subject.

[0142] The amatoxin analog or conjugate of the present disclosure may be administered or used alone or in combination with other therapeutic agents useful for treating a disease (e.g. cancer). When administered or for use in combination with other known therapeutic agents, it is an embodiment that the amatoxin analog or conjugate of the present disclosure is administered or for use contemporaneously with those therapeutic agents. As used herein, the term “contemporaneous” in reference to administration of two substances to a subject or use means providing each of the two substances so that they are both biologically active in the individual at the same time. The exact details of the administration or use will depend on the pharmacokinetics of the two substances in the presence of each other, and can include administration or use of the two substances within a few hours of each other, or even administration or use of one substance within 24 hours of administration or use of the other, if the pharmacokinetics are suitable. Design of suitable dosing regimens is routine for a person skilled in the art. In some embodiments of the present disclosure, two substances will be administered or for use substantially simultaneously, i.e. within minutes of each other, or in a single composition that includes both substances. It is a further embodiment of the present disclosure that a combination of the two substances is administered to a subject or for use in a non-contemporaneous fashion.

[0143] The dosage of the amatoxin analog or conjugate of the disclosure can vary depending on many factors such as the pharmacodynamic properties of the amatoxin analog or conjugate, the age, health and / or weight of the subject, the nature and / or extent of the symptoms of the disease, the frequency of the treatment or use and the type of concurrent treatment or use, if any, and the clearance rate of the amatoxin analog or conjugate in the subject. A person skilled in the art can determine the appropriate dosage based on the above factors. In an embodiment, the amatoxin analog or conjugate of thepresent disclosure is administered or for use initially in a suitable dosage that is optionally adjusted as required, depending on the clinical response.

[0144] The present disclosure also includes a kit comprising an amatoxin analog as described herein, a linker as described herein and optionally instructions for preparing a amatoxin-linker construct as described herein from the amatoxin analog and the linker. The present disclosure also includes a kit comprising an amatoxin analog as described herein, a linker as described herein, a target-binding moiety as described herein and optionally instructions for preparing a conjugate as described herein from the amatoxin analog, the linker and the target-binding moiety. The present disclosure also includes a kit comprising an amatoxin-linker construct as described herein, a target-binding moiety and optionally instructions for preparing a conjugate as described herein from the amatoxin-linker construct and the target-binding moiety. IV. Methods of Preparation

[0145] It will be appreciated by a person skilled in the art that some embodiments relating to R1acan be varied as described herein in relation to R1with the addition of the options that the embodiments relating to R1acan include a protected form of the embodiments of R1or a moiety that is precursor to the moieties listed as embodiments of R1. The protecting group for the protected form of the embodiments of R1may depend, for example, on the identity of the functional group and / or the synthetic manipulation to be performed, but the selection of a suitable protecting group can be readily made by a person skilled in the art.

[0146] The present disclosure includes a method of preparing a dihydroxyisoleucine (DHIle) analog, the method comprising: (i) saponification of a lactone of Formula IV to provide a diol of Formula V: , wherein: R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; andPG1is a protecting group; and optionally further comprising: (ii) protection of the diol of Formula V to provide a compound of Formula VI: , wherein: R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; and PG1and PG2are each independently protecting groups; and (ii) conversion of the compound of Formula VI to the NHS ester of Formula II: , wherein: R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; and PG1and PG2are each independently protecting groups; and wherein each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl.

[0147] In an embodiment, the method comprises the saponification of the lactone of Formula IV to provide the diol of Formula V, protection of the diol of Formula V to provide the compound of Formula VI, and conversion of the compound of Formula VI to the NHS ester of Formula II.

[0148] The conditions for saponification of the lactone of Formula IV to provide the diol of Formula V can be any suitable conditions. In an embodiment, the conditions comprise reacting the lactone of Formula IV with a suitable base (for example, an alkali metal hydroxide such as lithium hydroxide) to convert the lactone of Formula IV to the corresponding carboxylate salt followed by neutralization of the carboxylate salt with a suitable acid (for example, HCl) to obtain the diol of Formula V.

[0149] The conditions for protection of the diol of Formula V to provide the compound of Formula VI can be any suitable conditions, the selection of which may depend, for example, on the identity of R1aand / or PG2. In an embodiment, PG2is a silyl ether. In an embodiment, PG2is tert-butyldimethylsilyl. In an embodiment, the conditions comprise treatment of the diol of Formula V with tert-butyldimethylsilyl chloride.

[0150] The conditions for conversion of the compound of Formula VI to the NHS ester of Formula II can be any suitable conditions. In an embodiment, the conditions comprise reaction of the compound of Formula VI with N,N’-disuccinimidyl carbonate.

[0151] In an embodiment, R1ais other t R is -SRi7R O8, w HhNer PeGin1han H, an each R8is indepe1d na the lactone of Formula IV is prepared by a method comprising: (i) conversion of the silyl enol ether of Formula VII to t de Ohe γ ntly H-k CNe 1 Pto -6G-i al1soleucine of Formula VIII: rein: PG1is a pro (VteIcIt)ing g OrEotup; 7 R (VIII) O OkyElt,whe O or aryl; and R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; and(ii) reduction of the γ-keto-isoleucine of Formula VIII to obtain the lactone of Formula IV: , wherein: PG1is a protecting group; R1ais OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', -ON(R ')2, - N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto.

[0152] The present disclosure also includes a method of preparing a γ-keto-is PG1is 2R a7 p Orote HcNtin P( Og OG g ) Or 2REotup; R7is -SiR8, wherein each R8is indep ', -SeR ' or -N Re (R1nade ')N Ontly (R) HI C 2)N1 , a P- O6 pGal r Oky otEl etoleucine of Formula VIII, the method comprising conversion of the silyl enol ether of Formula VII to the γ-keto-isoleucine of Formula VIII:1 1,wherein: (VII) (VII or aryl; and R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R '), -N(R ')OR ', -S cted form thereof or a precursor thereto.

[0153] In an embodiment, R1ais OH and the conversion of the silyl enol ether of Formula VII to the γ-keto-isoleucine of Formula VIII comprises Rubottom oxidation.

[0154] In an embodiment, R1ais Br, and the conversion of the silyl enol ether of Formula VII to the γ-keto-isoleucine of Formula VIII comprises electrophilic bromination of the silyl enol ether of Formula VII to provide a δ-bromo-γ-keto-isoleucine of Formula VIII.

[0155] In an embodiment, the method further comprises nucleophilic substitution of R1ain the ^-bromo-γ-keto-isoleucine of Formula VIII. In another embodiment, the nucleophilic substitution provides a ^-fluoro-γ-keto-isoleucine of Formula VIII.

[0156] The conditions for reduction of the γ-keto-isoleucine of Formula VIII to obtain the lactone of Formula IV can be any suitable conditions. In an embodiment, the conditions comprise borane-THF reduction with the 2-methyl-CBS-oxazaborolidine catalyst.

[0157] In an embodiment, the method further comprises nucleophilic substitution of R1ain the lactone of Formula IV. In another embodiment, the nucleophilic substitution provides a lactone of Formula IV, wherein R1ais N3, -SH, -S-S-tBu or -S-S-CH(CH3)CH(CH3)2.

[0158] In an embodiment, R1ais -SH and the method comprises: nucleophilic displacement of bromine with a suitable source of thioacetate such as an alkali metal ethanethioate (e.g., potassium ethanethioate) followed by treatment with a suitable reagent (e.g., hydrazine) to obtain the lactone of Formula IV, wherein R1ais SH.

[0159] In an embodiment, R1ais -S-S-R '. In another embodiment, R1ais -S-S-tBu or -S- S-CH(CH33)CH(CH H33S). In su Och em Obo+dimHents, the method erein R is SH w such as CsCOR)' ca ith to Sn H o S further S-R ' u btain th O comprise: reacting the lactone of For HmNula IV, whS R'1aHn eNder lac O suitable conditions (e.g., in the presence of a suitPaGbl1e base2 3Boctone of Formula IV, wherein R1ais -S-S-R ' such as wherein R1ais -S-S-tBu or -S-S-CH(CH33)CH(CH33).

[0160] The present disclosure also includes a method of preparing a (2S,3R,4S) dihydroxyisoleucine (DHIle) analog, wherein the reduction of the γ-keto-isoleucine of Formula VIII as described herein further or alternatively provides a compound of Formula IX: ,wherein: PG1is a protecting group; and R1ais OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', -ON(R ')2, - N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto, the method comprising: (i) removal of the ethyl group to provide a diol of Formula V ': , wherein: PG1is a protecting group; and R1ais OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', -ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; and optionally further comprising: (ii) protection of the diol of Formula V ' to provide a compound of Formula VI ': , wherein: R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', -ON(R ')2, - N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; and PG1and PG2are each independently protecting groups; and (iii) conversion of the compound of Formula VI ' to the NHS ester of Formula II ': , wherein:R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; and PG1and PG2are each independently protecting groups.

[0161] In an embodiment, the method comprises the protection of the diol of Formula V ' to provide the compound of Formula VI '; and the conversion of the compound of Formula VI ' to the NHS ester of Formula II '.

[0162] In an embodiment, R1ais F.

[0163] The conditions for removal of the ethyl group to provide the diol of Formula V ' can comprise any suitable conditions. In an embodiment, the conditions comprise reaction of the diol of Formula V ' with a suitable base such as an alkali metal hydroxide (e.g., LiOH).

[0164] The conditions for protection of the diol of Formula V ' to provide a compound of Formula VI ' can be any suitable conditions, the selection of which may depend, for example, on the identity of R1aand / or PG2. In an embodiment, PG2is a silyl ether. In an embodiment, PG2is tert-butyldimethylsilyl. In an embodiment, the conditions comprise treatment of the diol of Formula V ' with tert-butyldimethylsilyl chloride.

[0165] The conditions for conversion of the compound of Formula VI ' to the NHS ester of Formula II ' can be any suitable conditions. In an embodiment, the conditions comprise reaction of the compound of Formula VI ' with N,N'-disuccinimidyl carbonate.

[0166] In an embodiment, the silyl enol ether of Formula VII is prepared by a method comprising reacting a γ-keto-isoleucine of Formula X with a silane of Formula XI in the presence of a base: wherein: PG1is a protecting group; each R8is independently C1-6alkyl or aryl; and R9is a hydrolysable group.

[0167] The hydrolysable group can be any suitable hydrolysable group, the selection of which can be made by a person skilled in the art. In an embodiment R9is chloro. In an embodiment, each R8is independently C1-6alkyl. In an embodiment each R8is methyl.

[0168] In an embodiment, the compound of Formula X is prepared by a method comprising: removal of the p-methoxyphenyl (PMP) group from a γ-keto-L-isoleucine of Formula XII followed by protection of the amino group to provide the compound of Formula X: .

[0169] The conditions for removal of the PMP can be any suitable conditions. In an embodiment, the conditions comprise treatment with trichloroisocyanuric acid.

[0170] The conditions for protection of the amino group to provide the compound of Formula X can be any suitable conditions, the selection of which may depend, for example, on the identity of PG1. In an embodiment, PG1is Boc. In an embodiment, the conditions comprise reaction with (Boc)2O in the presence of a suitable base.

[0171] In an embodiment, R1is H, and the lactone of Formula IV is prepared by a method comprising: (i) reduction of a γ-keto-isoleucine of Formula XII to provide a lactone of Formula IV(a): and protection of the lactone of Formula XV(a) to provide the lactone of Formula IV.

[0172] The conditions for reduction of the γ-keto-isoleucine of Formula XII to provide the lactone of Formula IV(a) can comprise any suitable conditions. In an embodiment, the conditions comprise treatment with trichloroisocyanuric acid.

[0173] The conditions for protection of the lactone of Formula XV(a) to provide the lactone of Formula IV can comprise any suitable conditions, the selection of which may depend, for example, on the identity of PG1. In an embodiment, PG1is Boc. In an embodiment, the conditions comprise reaction with (Boc)2O in the presence of a suitable base.

[0174] In an embodiment, the γ-keto-L-isoleucine of Formula XII is prepared by a method comprising: (i) L-proline-catalyzed Mannich reaction of p-methoxyphenyl-iminoester of Formula XIII with butanone to provide γ-keto-L-allo-isoleucine of Formula XIV: ; and (ii) catalytic epimerization of the γ-keto-L-allo-isoleucine of Formula XIV to provide the γ-keto-L-isoleucine of Formula XII: .

[0175] The conditions for the catalytic epimerization of the γ-keto-L-allo-isoleucine of Formula XIV to provide the γ-keto-L-isoleucine of Formula XII can comprise any suitable conditions. In an embodiment, the conditions comprise reaction of the γ-keto-L-allo- isoleucine of Formula XIV with 1,5-diazabicyclo[4.3.0]non-5-ene (DBN).

[0176] In an embodiment, the p-methoxyphenyl-iminoester of Formula XIII is prepared by reaction of p-anisidine with ethyl glyoxalate.

[0177] In an embodiment, the method is for preparing a dihydroxyisoleucine (DHIle) analog of Formula III(a): , the method comprising deprotection of the diol of Formula V or Formula V ' to provide the compound of Formula III. The conditions for deprotection can be any suitable conditions, which may depend, for example, on the identity of R1aand / or R1as well as the identity of the protecting groups. A person skilled in the art could readily select such conditions.

[0178] The present disclosure also includes use of a compound of Formula II as described herein or an NHS ester of Formula II or Formula II ' prepared by a method as described herein in the preparation of an amatoxin or an amatoxin analog.

[0179] The present disclosure also includes a method of preparing an α-amanitin or an α-amanitin analog, the method comprising coupling a compound of Formula II as described herein or an NHS ester of Formula II or Formula II ' prepared by a method as described herein to a monocyclic heptapeptide α-amanitin or α-amanitin analog precursor, followed by deprotection and macrolactamization. The monocyclic heptapeptide α-amanitin or α- amanitin analog precursor can be prepared by any suitable method. For example, the preparation can comprise a method in line with that reported Matinkhoo et al. (2018) or variations thereof, which may depend, for example, on the identity of the residues in the monocyclic heptapeptide α-amanitin or α-amanitin analog precursor.

[0180] In an embodiment, PG is tert-butyloxycarbonyl and the conditions for deprotection comprise HCl having a concentration of about 1 M in a solvent comprising Et2O.

[0181] In another embodiment, R1is N3, and the method further comprises reduction of the α-amanitin analog to convert R1into an NH2and / or an epoxide.

[0182] The present disclosure also includes a dihydroxyisoleucine (DHIle) analog of the Formula II: , wherein R1ais H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2, a protected form thereof or a precursor thereto; and PG1and PG2are each independently protecting groups.

[0183] In an embodiment, R1is H, O-PG3, N(R ')2, SR ', halo, -N3or -S-S-R '. In another embodiment, R1is H, O-PG3, N(R ')2, SR ', halo, -N3or -S-S-R ', wherein R ' is H or C1-6alkyl. In a further embodiment, R1is H, O-PG3, F, Br, -N3, -S-S-tBu, SH or -S-S- CH(CH3)CH(CH3)2. In another embodiment, R1is H, O-PG3, F, Br, -N3, -S-S-tBu or NH2. In an embodiment, R1is F, Br, -N3, -S-S-tBu, SH or -S-S-CH(CH3)CH(CH3)2. In an embodiment, R1is H. In another embodiment, R1is O-PG3. In a further embodiment, R1is F. In another embodiment, R1is Br. In an embodiment, R1is -N3. In another embodiment, R1is -S-S-tBu. In a further embodiment, R1is NH2. In another embodiment, R1is SH. In a further embodiment, R1is -S-S-CH(CH3)CH(CH3)2.

[0184] PG1, PG2and PG3can be any suitable protecting groups, the selection of which can be made by a person skilled in the art. In an embodiment, PG1, PG2and PG3are capable of use in solid phase peptide synthesis (SPPS). In an embodiment, PG1is tert- butyloxycarbonyl. In another embodiment, PG2is tert-butyldimethylsilyl. In a further embodiment, O-PG3is a silyl ether. In another embodiment, PG3is tert-butyldimethylsilyl.

[0185] The present disclosure also includes a dihydroxyisoleucine (DHIle) analog of the Formula III: ,wherein R1is OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', -ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2; and each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, provided that R1is not OH.

[0186] In an embodiment, the compound of Formula III has the following stereochemistry: .

[0187] In an embodiment, the compound of Formula III has the following stereochemistry: .

[0188] In an embodiment, R1is OR ', N(R ')2, SR ', halo, -N3or -S-S-R '. In another embodiment, R1is N(R ')2, SR ', halo, -N3or -S-S-R ', wherein R ' is H or C1-6alkyl. In a further embodiment, R1is F, Br, -N3, -S-S-tBu, SH or -S-S-CH(CH3)CH(CH3)2. In another embodiment, R1is F, Br, -N3, or -S-S-tBu. In an embodiment, R1is F. In another embodiment, R1is Br. In an embodiment, R1is -N3. In another embodiment, R1is -S-S-tBu. In another embodiment, R1is SH. In a further embodiment, R1is -S-S-CH(CH3)CH(CH3)2.

[0189] In an embodiment, R ' is H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is unsubstituted. In another embodiment, R ' is H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl. In a further embodiment, each R ' is independently H or C1-20alkyl. In an embodiment, R ' is C1-6alkyl. In another embodiment, R ' is H.

[0190] The present disclosure also includes a compound of Formula VII: , wherein: PG1is a protecting group; and R7is -SiR8, wherein each R8is independently C1-6alkyl or aryl.

[0191] In an embodiment, PG1is Boc. In an embodiment, each R8is independently C1-6alkyl. In an embodiment each R8is methyl.

[0192] The present disclosure also includes a compound of Formula VIII: , wherein: PG1is a protecting group; and R1ais OH or a protected form thereof or halo.

[0193] In an embodiment, PG1is Boc. In another embodiment, R1ais OH. In an embodiment, R1ais bromo. In another embodiment, R1ais fluoro.

[0194] The present disclosure also includes a compound of Formula IV(b): , wherein: PG1is a protecting group; R1ais SR ' or -S-S-R '; and each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl.

[0195] In an embodiment, PG1is Boc. In another embodiment, R1ais SR '. In another embodiment, R1ais SH. In a further embodiment, R1ais -S-S-R '. In another embodiment, R1ais -S-S-tBu. In an embodiment, R1ais -S-S-CH(CH3)CH(CH3)2.

[0196] The following non-limiting examples are illustrative of the present disclosure: EXAMPLES I. Materials, Equipment and Analytical Methods

[0197] Unless otherwise stated, all reactions were performed under argon atmosphere in flame-dried glassware and anhydrous solvents at room temperature. Controlled temperature reactions were performed using a mineral oil bath and a temperature-controlled hot plate (IKA Ceramag Midi). Temperatures below room temperature were achieved in an ice / water bath (0 °C), and dry ice / acetone bath (-78 °C). Solvents were removed under reduced pressure using a Büchi rotary evaporator. Anhydrous solvents were prepared by distillation under a nitrogen atmosphere. DMSO, THF and DMF were dried over 4Å molecular sieves under argon atmosphere. n-Butyl lithium solutions in tetrahydrofuran were titrated with di- phenylacetic acid (DPAA) to the yellow endpoint. Unless otherwise indicated, all reagents and solvents were purchased from Sigma-Aldrich, Alfa Aesar, Acros Organics, OakwoodChemicals and TCI America. Thin-layer chromatography (TLC) was performed using silica gel 60 F254precoated aluminium plates (EM Science). Detection of TLC spots was performed using an ultraviolet (UV) lamp at 254 nm, p-anisaldehyde, potassium permanganate, ninhydrin, 2,4-dinitrophenylhydrazine and bromo cresol green prepared according to literature procedures. Flash column chromatography purifications were performed using silica gel 60 (230-400 mesh, Silicycle, Quebec). Low-resolution mass spectra (LRMS) in electrospray ionization (ESI) mode were obtained from a Bruker Esquire spectrometer. Proton (1H NMR) and carbon (13C NMR) spectra were obtained using a Bruker AV-300 (300 MHz), AV-400 (400MHz) DIR and AV-400 (400MHz) INV spectrometer. II. Detailed chemical methods for synthesis of selected compounds (a) Synthesis of p-methoxyphenyl-iminoester (1):

[0198] Anhydrous dichloromethane (DCM, 90 ml) was added into a flame dried 3-neck round bottom flask with a magnetic stirrer and pre-activated 4 Å molecular sieves (37 g) under argon. p-Anisidine (6 g, 48.6 mmol) was added, and the solution was stirred at room temperature. A 50% solution of ethyl glyoxylate in toluene (12 ml, 58.8 mmol) was added dropwise using a dropping funnel over 1 hour. Then the reaction mixture was stirred and heated at 40 °C in an oil bath for 24 hours. After that, the mixture was filtered, and the sieves were washed with DCM. The filtrate was concentrated under reduced pressure to give the reddish-brown crude product. The crude was purified on silica gel using flash column chromatography (DCM:TEA 99:1). Yield: 92%. Rf: 0.22 (100% DCM) (UV).1H NMR: (CD2Cl2, 400 MHz): δ 7.90 (s, 1H), 7.32 (d, J=8.96 Hz, 2H), 6.92 (d, J=8.95 Hz, 2H), 4.33 (q, J 7.14, 7.14, 7.14 Hz, 2H), 3.79 (s, 3H), 1.35 (t, J 7.14, 7.14 Hz, 3H).13C NMR: (CD2Cl2, 100 MHz): δ 163.97, 161.06, 148.56, 141.91, 123.99, 115.01, 62.09, 55.97, 14.49. HRMS- ESI (m / z): [M+H]+calculated for C11H13NO3H , 208.0975: found 208.0975.(b) Synthesis of γ-keto-L-allo-isoleucine (2):

[0199] N-paramethoxyphenyl (PMP) protected α-amino ethyl acetate (9.38 g, 47.2 mmol) was dissolved in anhydrous dimethylsulfoxide (DMSO, 350 ml). Butanone (8.46 ml, 94.4 mmol) was added dropwise using a syringe followed by L-proline (1.08 g, 9.45 mmol) at room temperature. The reaction mixture was stirred at room temperature for 24 hours. Aqueous workup was performed with half saturated NH4Cl (3 × 25 ml) and the aqueous layer was extracted with ethyl acetate (3 × 30 ml). The combined organic layer was washed with brine and dried over anhydrous sodium sulphate. Ethyl acetate was removed under reduced pressure to give the crude product. The crude was purified on silica gel using flash column chromatography (EtOAc:Hexane 15:85 v / v) to afford the product as a yellowish oil. Yield: 70%. Rf: 0.38 (EtOAc:Hexane 30:70 v / v) (UV).1H NMR: (CD2Cl2, 400 MHz): δ 6.76 (d, J=8.98 Hz, 2H), 6.62 (d, J=8.93 Hz, 2H), 4.32 (dd, J=5.75, 9.99 Hz, 1H), 4.12 (q, J= 7.27, 7.27, 7.44 Hz, 2H), 3.91 (d, J=10.18 Hz, 2H), 3.71 (s, 3H), 2.98-3.07 (m, 1H), 2.20 (s, 3H), 1.19-1.24 (m, 6H).13C NMR: ( CD2Cl2, 100 MHz): δ 209.25, 173.16, 153.61, 141.56, 116.08, 115.22, 61.77, 59.85, 56.05, 49.63, 28.75, 14.50, 12.42. HRMS-ESI (m / z): [M+H]+calculated for C15H21NO4H , 280.1549: found 280.1548. (c) Synthesis of γ-keto-L-isoleucine (3):

[0200] Anhydrous THF (250 ml) was added to a flame dried round bottom flask under argon. γ-keto-L-allo-Isoleucine 2 (5.9 g, 21.12 mmol) was added followed by 1,5- diazabicyclo(4.3.0)non-5-ene (DBN, 0.2 ml, 1.68 mmol). The resulting solution was stirredunder argon for 2 hours at room temperature. After that, it was stirred open to the atmosphere at room temperature for 24 hours. The solvent was removed under reduced pressure to obtain the crude product. The crude was dissolved in a minimum amount of boiling ethanol and kept at -20° C. A white crystalline solid was obtained which was filtered and washed with cold ethanol to give the pure product. Yield: 60%. Rf: 0.40 (EtOAc:Hexane 30:70 v / v) (UV).1H NMR: (CD2Cl2, 400 MHz): δ 6.76 (d, J=8.96 Hz, 2H), 6.65 (d, J=8.96 Hz, 2H), 4.10-4.22 (m, 4H), 3.72 (s, 3H), 3.02 (p, J=7.13, 7.13, 7,27, 7.27 Hz, 1H), 2.21 (s, 3H), 1.17-1.24 (m, 6H).13C NMR: (CD2Cl2, 100 MHz): δ 209.83, 173.01, 153.61, 141.52, 116.08, 115.28, 61.75, 60.83, 56.10, 49.83, 29.08, 14.53, 13.49. HRMS-ESI (m / z): [M+H]+calculated for C15H21NO4H , 280.1549: found 280.1550. (d) Synthesis of Compound 4:

[0201] A solution of γ-keto-L-isoleucine 3 (710 mg, 3.01 mmol) was prepared in 32 ml of acetonitrile / water mixture (1:1 v / v). The solution was stirred in an ice bath followed by the addition of trichloroisocyanuric acid (TCCA, 422 mg, 1.81 mmol) and 2 M HCl (3 ml, 6.02 mmol). The reaction mixture was stirred at 0 °C in an ice bath for 2 hours. After the completion of the reaction, acetonitrile (ACN) was removed under reduced pressure and the aqueous layer was extracted with DCM (2 × 10 ml). The aqueous layer was taken ahead, and the pH of the aqueous layer was adjusted to 9-10 using 2 M Na2CO3. The aqueous layer was again extracted with DCM (5 × 15 ml). The organic layer was washed with brine and dried over anhydrous sodium sulphate. The solvent was evaporated under reduced pressure to give the crude product. The crude was immediately taken ahead without any purification. Crude (390 mg, 3.01 mmol) was dissolved in DCM (16 ml) and stirred at 0 °C. N,N- Diisopropylethylamine (DIPEA, 1.05 ml, 6.02 mmol) was added followed by the addition of di-tert-butyl dicarbonate (721 g, 3.31 mmol). The reaction mixture was warmed to room temperature over 24 hours. After completion, the reaction mixture was poured into saturated NH4Cl (15 ml) and was extracted with ethyl acetate (3 × 10 ml). The organic layer waswashed with NaHCO3and brine and dried over anhydrous sodium sulphate. The solvent was evaporated under reduced pressure to give the crude product. The crude was purified on silica gel using flash column chromatography (EtOAc:Hexane 15:85 v / v) to afford the product. The product was crystallised from ethyl acetate giving needle-like crystals to confirm the desired stereochemistry. Yield: 55% over 2 steps. Rf: 0.45 (EtOAc:Hexane 30:70 v / v) (Ninhydrin Stain).1H NMR: (CD2Cl2, 400 MHz): δ 5.43 (d, J=9.36 Hz, 1H), 4.39 (dd, J= 4.02, 9.68 Hz, 1H), 4.12 (qd, J=1.75, 7.07, 7.08 Hz, 2H), 3.23-3.32 (m, 1H), 2.15 (s, 3H), 1.43 (s, 9H), 1.19-1.24 (m, 6H).13C NMR: (CD2Cl2, 100 MHz): δ 211.06, 171.61, 156.55, 80.07, 61.98, 55.63, 48.95, 28.58, 28.51, 14.44, 13.38. HRMS-ESI (m / z): [M+Na]+calculated for C13H23NO5Na , 296.1474: found 296.1472. (e) Synthesis of Silyl enol ether (5):

[0202] Anhydrous THF (6.25 ml) was placed in a flame dried round bottom flask under argon. It was immersed in a dry ice acetone bath maintaining a temperature of -78 °C. Diisopropanolamine (DIPA, 0.715 ml, 4.57 mmol) was added slowly followed by dropwise addition of (1.30 M) n-BuLi (3.52 ml, 4.57 mmol) using a syringe. A mixture of Trimethylsilyl chloride (TMSCl, 4.81 ml, 12.6 mmol) in anhydrous THF (6.25 ml) was prepared at room temperature in a flame dried round bottom flask. After the reaction mixture was stirred for 30 minutes at -78 °C; the mixture of TMSCl in THF was added dropwise using a syringe. After 15 minutes of stirring, Compound 4 (0.5g, 1.8 mmol) dissolved in anhydrous THF (6.25 ml) in a flame dried round bottom flask was added dropwise with a syringe. After that reaction mixture was stirred for 2 hours at -78 °C triethylamine (TEA, 3.75 ml) was added to the mixture and stirred for 20 minutes. After that NaHCO3(15 ml) was added to quench the reaction and was extracted with EtOAc (3 × 15 ml). The organic layer was washed with water, saturated KH2PO4, brine and dried over anhydrous sodium sulphate. The solvent was evaporated under reduced pressure to give the crude product. The crude was immediately taken ahead without any purification. Rf: 0.82 (EtOAc:Hexane 40:60 v / v) (Ninhydrin Stain).(f) Rubottom oxidation of 5 to prepare N-boc- ^-hydroxy- γ-keto-L-isoleucine ethyl ester (6):

[0203] An aqueous solution of 5% NaHCO3(473 mg) was prepared in 10 ml of water. Silyl enol ether 5 (625 mg, 1.81 mmol) was dissolved 10 ml DCM and was stirred at 0 °C. A solution of 5% NaHCO3was added to the reaction mixture followed by meta- chloroperoxybenzoic acid (mCPBA, 705 mg, 2.72 mmol). The reaction mixture was stirred at 0 °C for 2 hours. After that, the reaction mixture was quenched saturated solution of sodium thiosulphate (10 ml) and extracted with DCM (3 × 10 ml). The organic layer was washed with brine and dried over anhydrous sodium sulphate. The solvent was evaporated under reduced pressure to give crude, which was immediately dissolved in 20 ml THF and was stirred at 0 °C.1 M solution of tetra-n-butylammonium fluoride (TBAF) in THF (1.81 ml.1.81 mmol) was added and the mixture was stirred at 0 °C for 4 hours. The reaction mixture was washed with brine (15 ml) and extracted with ethyl acetate (3 × 10 ml). The organic layer was dried over anhydrous sodium sulphate and the solvent was evaporated under reduced pressure to give the crude product. The crude was purified on silica gel using flash column chromatography (EtOAc:Hexane 20:80 v / v). Rf: 0.13 (EtOAc:Hexane 40:60 v / v) (Ninhydrin Stain).1H NMR: (CD2Cl2, 400 MHz): δ 5.45 (d, J=8.31 Hz, 1H), 4.50 (dd, J= 3.84, 9.89 Hz, 1H), 4.34 (s, 1H), 4.29 (s, 1H), 4.15 (q, J=7.09, 7.37, 7.37 Hz, 2H), 3.26- 3.29 (m, 1H), 2.90 (s, 1H), 1.43 (s, 9H), 1.20-1.24 (m, 6H).13C NMR: (CD2Cl2, 100 MHz): ^ 212.30, 171.18, 156.20, 80.29, 67.50, 62.14, 55.62, 44.69, 28.38, 14.24, 13.09. HRMS- ESI (m / z): [M+Na]+calculated for C13H23NO6Na , 312.1423: found 312.1419. (g) Synthesis of Lactone (7):

[0204] Anhydrous THF (6 ml) was placed in a flame dried round bottom flask and (R)- 2-methyl-CBS-oxazaborolidine (R-CBS, 57.54 mg, 0.207 mmol) was added and thesolution was stirred at room temperature.1 M solution of borane in THF (2.07 ml, 2.07 mmol) was added dropwise and the resulting solution was stirred for 30 min. N-boc- δ- Hydroxy- γ-keto-L-isoleucine ethyl ester 6 (200 mg, 0.69 mmol) dissolved in anhydrous THF was added dropwise to the reaction mixture over 30 minutes. The resulting mixture was stirred at room temperature overnight. The reaction was cooled in an ice bath and was quenched with methanol (1 ml). The crude was concentrated under reduced pressure and was purified on silica gel using flash column chromatography (EtOAc:Hexane 15:85 v / v) to afford the product. The desired stereochemistry was confirmed by 2D COSY (1H,1H) (FIG.1 and Table 1) and NOESY (1H,1H) (FIG.2 and Table 2). Rf: 0.60 (EtOAc:Hexane 90:10 v / v) (Ninhydrin stain).1H NMR: (CD2Cl2, 300 MHz): δ 5.02 (bs, 1H), 4.64 (t, J=7.57, 7.57, 1H), 4.23-4.26 (m, 1H), 3.89 (dd, J=2.94, 12.93, 1H), 3.79 (dd, J=4.23, 12.28, 1H), 2.72-2.80 (m, 1H), 1.44 (s, 9H), 1.02 (d, J=7.25, 3H).13C NMR: (CD2Cl2, 100 MHz): δ 176.03, 155.18, 86.52, 80.71, 63.68, 61.56, 35.30, 28.90, 13.96. HRMS-ESI (m / z): [M+Na]+calculated for C11H19NO5Na, 268.1160: found 268.1159. Table 1. Correlation table of lactone 7 (COSY (1H,1H)).Table 2. Correlation table of lactone 7 (NOESY (1H,1H)).(h) Synthesis of Diol (8) and subsequent protection to afford Compound 9:

[0205] Lactone 7 (40 mg, 0.16 mmol) was dissolved in THF (2 ml) and water (1 ml). Lithium hydroxide (7.2 mg, 0.4 mmol) was added to the reaction mixture. The reaction was stirred at room temperature. Upon completion, the pH of the mixture was adjusted to around 2-3 using 0.1 M HCl. After that, it was extracted using EtOAc (3 × 5 ml). The organic layer was washed with brine and dried over anhydrous sodium sulphate. The yellowish crude (42 mg, 0.16 mmol) was dissolved in 3.3 ml dimethylacetamide (DMA) followed by the addition of imidazole (108 mg, 1.6 mmol) and tert-butyldimethylsilyl chloride (TBSCl, 192 mg, 1.28 mmol). Another 60 mg of imidazole was added to adjust the pH to 8 and the reaction mixture was stirred for 24 hours. After the completion of the reaction, pH was adjusted to 2-3 using 0.1 M HCl and extracted with EtOAc (4 × 5 ml). The organic layer was washed with water, and brine and was dried over anhydrous sodium sulphate. The crude was purified on silica gel using flash column chromatography (DCM:MeOH:AcOH (98.9:1:0.1 v / v) to afford the product. Rf: 0.22 (MeOH:DCM 2.5 / 97.5 v / v) 6 drops acetic acid (BCG stain).1H NMR: (CD2Cl2, 400 MHz): δ 5.99 (d, J=5.89 Hz, 1H), 4.40 (dd, J=3.90, 7.30 Hz 1H,), 3.72 (m, 3H), 2.39 (s, 1H), 1.42 (s, 9H), 1.03 (d, J=7.30 Hz, 3H), 0.91 (d, J=2.69 Hz, 9H), 0.10 (m, 6H).13C NMR: CD2Cl2, 100 MHz): δ 174.32, 156.29, 79.91, 76.23, 65.42, 39.04, 30.10, 28.49, 26.06, 25.99, 18.64, 18.40, 13.99, -3.89, -4.28, -4.78, -5.37. HRMS-ESI (m / z) of 8: [M+Na]+calculated for C23H49NO6Si2Na , 514.2996: found 514.2992.

[0206] (200 mg, 0.816 mmol) of lactone 7 was dissolved in THF (18 mL) and water (9 mL).2 mL of sodium carbonate / bicarbonate aqueous buffer (0.1 M) pH 9.2 was added to the solution. A stock solution of lithium hydroxide (40 mg, 1.67 mmol) was prepared in 6 mL of water. A small portion of lithium hydroxide (0.25 mL) was added at 30-minute intervals to the reaction mixture. The reaction was monitored by TLC and mass spectrometry. Upon completion, the pH of the mixture was adjusted to about 2 using 1 M HCl. After that, it was extracted using EtOAc (3 × 25 mL). The organic layer was washed with brine and dried over anhydrous sodium sulfate. The yellowish crude was dissolved in 25 mL DMA followed by the addition of imidazole (0.56 g, 8.16 mmol) and TBS-Cl (0.98 g, 6.53 mmol). Another 0.2g of imidazole was added to adjust the pH to 8 and the reaction mixture was stirred for 24 hours. After the completion of the reaction, pH was adjusted to 2 using 0.1 M HCl and extracted with EtOAc (4 × 10 ml). The organic layer was washed with water, and brine and dried over anhydrous sodium sulphate. The crude was purified on silica gel using flash column chromatography (DCM:MeOH:AcOH (98.9:1:0.1 v / v) to afford 55% yield over 2 steps. Rf: 0.42(MeOH:DCM:AcOH 5:94:1 v / v) (Ninhydrin and BCG active).1H NMR: 1H NMR (CD2Cl2, 300 MHz): δ 5.96 (d, J = 6.1 Hz, 1H), 4.44 (dd, J = 7.3, 3.7 Hz, 1H), 3.81 – 3.64 (m, 3H), 2.41 (s, 1H), 1.42 (s, 9H), 1.04 (d, J = 7.3 Hz, 3H), 0.91 (d, J = 3.0 Hz, 18H), 0.11 (d, J = 7.1 Hz, 12H).13C NMR: (CD2Cl2, 100 MHz): δ 174.05, 156.20, 79.92,76.23, 65.39, 55.83, 39.12, 28.47, 25.97, 18.63, 18.40, 13.88, -4.30, -4.79, -5.39. HRMS-ESI (m / z): [M+Na]+calculated for C23H49NO6Si2Na , 514.2996: found 514.2992 (i) Synthesis of SPPS-compatible NHS-ester of DHIle (10):

[0207] Compound 9 (25 mg, 0.054 mmol) was dissolved in 1:1 v / v of ethyl acetate (EtOAc, 1 ml) and ACN (1 ml) and stirred at 0 °C. N,N'-Disuccinimidyl carbonate (DSC, 26.08 mg, 0.10 mmol) and collidine (0.019 ml, 0.14 mmol) were added subsequently and the reaction mixture was warmed to room temperature over 24 hours. The reaction mixture was diluted with ethyl acetate (30 ml); and the organic layer was washed with saturated KH2PO4, saturated NaHCO3, and brine and dried over anhydrous sodium sulphate. The crude was purified on silica gel using flash column chromatography (EtOAc:Hexane 25:75 v / v) to afford the product. Rf: 0.62 (EtOAc:Hexane 50:50 v / v) (Ninhydrin stain).1H NMR: (CD2Cl2, 400 MHz): δ 6.35 (d, J=8.45 Hz, 1H), 4.65 (dd, J=8.42, 5.69 Hz 1H,), 3.89 (dt, J=8.15, 4.28, 4.28 Hz 1H), 3.60 (m, 2 H), 2.81 (s, 4H), 2.48 (m, 1H), 1.43 (s, 9H), 1.11 (d, J= 7.08 Hz, 3H), 0.91 (d, J= 6.57 Hz, 9H), 0.09 (m, 12H).13C NMR: (CD2Cl2, 100 MHz): δ 169.26, 168.21, 155.87, 80.04, 74.19, 64.78, 39.46, 28.47, 26.15, 26.06, 26.01, 18.71, 18.31, 12.88, -4.43, -4.87, -5.29, -5.49. HRMS- ESI (m / z): [M+Na]+calculated for C27H52N2O8Si2Na , 611.3160: found 611.3181.II. Results, Discussion and Additional Chemical Methods

[0208] Synthetic routes toward DHIle involving conventional and finical approaches are reported herein, eliminating safety hazards and complications associated with previous routes. It is centered around elementary reaction annihilating strenuous conditions; thus, it can produce gram-scale quantities of DHIle. For example, the synthesis for preparation of NHS-ester of (2S,3R,4R)-DHIle is summarized in Scheme 2. Scheme 2. Overall reaction manifold for preparation of NHS-ester of (2S,3R,4R)-DHIle. Conditions : (a) DCM, 40 °C, 24 hours, 92%; (b) L-proline (0.2 eq.), DMSO, RT, 24 hours, 70%; (c) DBN (0.08 eq.), THF, RT, 24 hours, 65%; (d) TCCA, HCl (2 M), H2O / ACN (1:1), 0 °C, 2 hours; (e) Boc2O, DIPEA, DCM, 0 °C to RT, 24 hours, 55% (over 2 steps); (f) LDA (2.5 eq.), TMS-Cl (7 eq.), Et3N, THF, -78 °C, 4 hours; (g) mCPBA, NaHCO3, DCM, 0 °C, 2 hours; (h) TBAF (1 eq.), THF, 0 °C to RT, 4-5 hours; (i) (R)-CBS (0.3 eq.), BH3(THF)(1 M, 3 eq.), THF, RT, 24 hours; (j) LiOH (2.5 eq.), H2O / THF (1:2), RT, 24 hours; (k) TBSCl, imidazole, DMF, pH 8, RT, 24 hours; (l) DSC, collidine, EtOAc / MeCN (1:1), 4 °C to RT, 24 hours.

[0209] Herein, we report the concise synthesis of DHIle (Scheme 2). Commencing with readily available p-methoxyphenyl-iminoester 1 (Marin et al, 2010), generated from p-anisidine and ethyl glyoxalate in 92% yield, we effected a proline catalyzed Mannich reaction with 2-butanone to afford the γ-keto-L-allo-isoleucine (2). Catalytic epimerization at C3 using 1,5- Diazabicyclo[4.3.0]non-5-ene (DBN) (Marin et al., 2010) yielded the desired γ-keto-L-isoleucine (3). Following PMP removal (Verkade et al., 2006) and Boc installation, we confirmed the absolutestereochemistry of 4 through x-ray diffraction. Utilizing lithium diisopropylamide (LDA) in conjunction with trimethylsilyl chloride (TMS-Cl), we generated silyl enol ether 5 (Corey & Gross, 1984; Krizan & Martin, 1983), which underwent Rubottom oxidation (Rubottom et al., 1974; Rubottom et al., 1978) resulting in N-Boc-δ-hydroxy-γ-keto-L-isoleucine ethyl ester (6) in 55% yield (over 2 steps, n = 14). Ester 6 was subjected to borane-THF reduction using the R-CBS catalyst (Corey et al., 1987; Lohray et al., 1992); and the resultant diol spontaneously formed lactone 7 with good diastereoselectivity. Boc removal provided lactone 7a (not shown) that was crystallized for x- ray diffraction to confirm the absolute stereochemical configuration of 7a and therefore that of 7. Saponification of lactone 7 gave diol 8, which was protected by TBS-Cl treatment, resulting in 9. Subsequent conversion to the NHS ester provided a SPPS-compatible NHS-ester of DHIle 10. This method for obtaining Boc-protected DHIle 10 obviates the use of transition metals, highly reactive pyrophoric reagents, intricate transformations, and safety concerns associated with the use of cyanide in large-scale reactions. This synthetic pathway entails conventional, cost-effective steps minimizing the purification requirements at each stage, enhancing scalability, and making it more accessible for large-scale production. Whereas DBN was used to epimerize 2 to 3, β-proline may alternatively be used for the direct production of the anti-Mannich product (Zhang et al., 2006; Mitsumori et al., 2006; Garg & Tanaka, 2020). Silyl-enol ether 5 provides an especially attractive node for generating γ-halogenated DHIle analogs that may be transposed further. In addition, ketones 4 (or 6) provide an attractive handle for substitution.

[0210] With a streamlined synthesis of SPPS-compatible NHS-ester of DHIle 10 in hand (Example 1), its use was evaluated in a synthesis of the more synthetically tractable S-deoxo- 6′-deoxy,-5′-hydroxy amanitin A0, which displays equipotent cytotoxicity to that of α-amanitin (Pryyma et al., 2020). Following methodology previously reported (Matinkhoo et al., 2018), we first procured monocyclic heptapeptide precursor 11 via SPPS, followed by a modified Savige-Fontana tryptathionylation, to which 10 was coupled to give octapeptide 13 (Scheme 9) (n = 5). Whereas the integration of DHIle into the amanitin core has historically relied on Fmoc-protection, here the installation of a Boc-protected DHIle would hypothetically afford greater efficiency as Boc removal would occur concomitantly with TBS removal.Scheme 3. Proposed N-to-O acyl transfer under acidic conditions used in TBS / Boc removal resulting in loss of DHIle.

[0211] Nevertheless, under acidic conditions, the N-terminal DHIle undergoes retrograde scission, likely via an N-to-O acyl transfer mechanism with concomitant formation of lactone 15 consistent with scission reported for homoserine (Pirrung & Bakas, 2018). To resolve this issue, we explored various acidic conditions and adjusted reaction parameters (Table 3). Table 3. Optimization of conditions for Boc and TBS removal.[a]% conversion to 14 determined by HPLC analysis. Integrations were performed with standard Agilent data analysis software. Reactions were run on 0.2 µmol scale. The crude reaction mixture was dried under reduced pressure and analyzed by reverse-phase HPLC. The % conversion was determined by taking the ratio of A (peak tR:3.3) / ΣA (All peaks that display tryptathionine UV absorption profile), and the ratio between monocycles 14 and 12 was determined by taking the ratio of A (peak tR:3.3 min) / A (peak at tR:3.0 min) where A= integral area of the peak of interest determined using standard Agilent data analysis software.

[0212] We found that 1 M HCl in Et2O successfully removed both amine and diol-protecting groups in a single step without significant loss of product. Diethyl ether was chosen over alternative solvents owing to the propensity for the more polar product to precipitate thereby eliminating undesired lactonization. Quantitative coupling between 10 and heptapeptide 11 gave octapeptide 13. Application of the optimized deprotection methodology in acidified Et2O, followed by HPLC-purification gave 14 in yields of ca.38%. Monocyclic octapeptide 14 was subjected to SepPak desalting followed by final macrolactamization to amanitin A0 with near- quantitative conversion (peak-to-peak), and in a 61% isolated yield (n=3). When tested against HEK-293 cells, amanitin A0 showed an IC50(0.31 µM), a value comparable to that of α- amanitin IC50(0.39 µM). Due to its high acute toxicity, only milligram quantities of the final toxin were synthesized. Accordingly, an optimized method for incorporating N-Boc-DHIle into the amanitin core is reported, which has not been previously documented, opening the opportunity for incorporating other Boc-protected amino acids e.g. homoserine and its analogs into peptides, as they are highly susceptible to undergoing N-to-O acyl transfer.

[0213] Taking advantage of the synthetic route we also prepared further analogs of DHIle which were furthermore incorporated into the amanitin core.

[0214] For example, the synthesis of (2S,3R,4S)-Mono-OH-Ile is shown in Scheme 4. Scheme 4. Synthesis of (2S,3R,4S)-Mono-OH-Ile.Conditions: a) DCM, 40 °C, 4Å sieves, 24 hours, 92%; b) L-proline (0.2 eq.), DMSO, RT, 24 hours, 70%; c) DBN (0.08 eq.), THF, RT, 24 hours, 65%; d) NaBH4 (3 eq.), CH3COOH (6 eq.), THF, RT, 24 hours, 70% combined yield; e) TCCA (0.6 eq.), HCl (2M), ACN / H2O (1 / 1), 0 °C, 2 hours; f) (Boc)2O, DIPEA, DCM, 24 hours, 0 °C to RT, 55% over two steps, g) LiOH (2.5 eq.), H2O / THF (2 / 1), RT, 24 hours; h) TBSCl, imidazole, DMF, pH 8, RT, 24 hours, 35% over two steps; i) DSC, collidine, EtOAc / ACN (1 / 1), 4 °C to RT, 24 hours, 60%.

[0215] The synthetic route starts with a condensation reaction between p-anisidine and ethyl glyoxalate to give the (PMP)-protected imine of glycine ethyl ester. This undergoes L- proline catalyzed Mannich condensation with 2-butanone that results in γ-keto L-allo- isoleucine C1. Catalytic epimerization on the β carbon using a bulky non-nucleophilic base DBN (1,5-diazabicyclo[4.3.0]non-5-ene) results in a more stable and desired γ-keto-L- isoleucine C2. To elude the propensity of epimerization at the Cα position, the reduction was done in acidic conditions to neutralize the ethoxide generated in situ from lactonization. Immediately after reduction, acyclic alcohol lactonized, which resulted in a 5-membered lactone. PMP was removed from amine, and simultaneously it was protected with Boc (tert- butyloxycarbonyl). The single crystal X-ray diffraction (XRD) structure of boc-lactone C3 was obtained, which confirmed the absolute stereochemistry. Subsequently, saponification and protection of hydroxy and NHS-ester synthesis were accomplished to achieve solid-phase peptide synthesis (SPPS) compatible mono-hydroxy isoleucine.

[0216] The synthesis of (2S,3R,4S)-Fluoro-OH-Ile and (2S,3R,4R)-Fluoro-OH-Ile is shown in Scheme 5.Scheme 5. Synthesis of (2S,3R,4S)-Fluoro-OH-Ile and (2S,3R,4R)-Fluoro-OH-Ile. Conditions: a) TCCA, HCl (2M), H2O / ACN (1 / 1), 0 °C, 2 hours; b) (Boc)2O, DIPEA, DCM, 0 °C to RT, 24 hours, 55% (over 2 steps); c) LDA (2.5 eq.), TMSCl (7 eq.), Et3N, -78 °C, THF, 4 hours; d) NBS, THF, 0 °C, 2 hours, 75% over 2 steps; e) ZnF2(1.5 eq.), KF (1.5 eq.), ACN, 100 °C, 24 hours, pressure tube, 60%; f) NaBH4(3 eq.), CH3COOH (6 eq.), THF, RT, 24 hours, 70% combined yield; g) LiOH, pH 8-9, THF / H2O (2 / 1), RT; h) TBSCl, imidazole, DMF, pH 8, RT, 48 hours, 40% over 2 steps; i) DSC, collidine, EtOAc / ACN (1 / 1), 4 °C to RT, 24 hours, 55%; j) LiOH, pH 8-9, THF / H2O (2 / 1), RT; k) TBSCl, imidazole, DMF, pH 8, RT, 48 hours, 44% over 2 steps; l) DSC, collidine, EtOAc / ACN (1 / 1), 4 °C to RT, 24 hours, 55%.

[0217] As shown in Scheme 5, PMP was removed from C2 and subsequently, protection of amine was carried out with Boc, and single-crystal XRD was obtained which confirmed the absolute stereochemistry of C4. LDA (lithium diisopropylamide) along with TMSCl (trimethylsilyl chloride) generated the silyl enol ether, followed by electrophilic bromination using NBS (N-bromosuccinimide) which resulted in δ-bromo-γ-keto-isoleucine C5. Nucleophilic substitution of bromine at ^-carbon position using fluoride ion gave the δ-fluoro- γ-keto-isoleucine C6. Similar reduction conditions were followed to obtain both epimers of δ- fluoro-γ-hydroxy-isoleucine and (SPPS) compatible versions were accomplished.

[0218] The synthesis of (2S,3R,4R)-Azido-OH-Ile is shown in Scheme 6 and the synthesis of (2S,3R,4R)-tBu-Disulphide-OH-Ile is shown in Scheme 7. Scheme 6. Synthesis of (2S,3R,4R)-Azido-OH-Ile. Conditions: a) NaBH4 (3 eq.), CH3COOH (6 eq.), THF, RT, 24 hours, 63%; b) NaN3(1.5 eq.), DMF, RT overnight, 62%; c) LiOH, pH 8-9, THF / H2O (2 / 1), RT; d) TBSCl, imidazole, DMF, pH 8, RT, 48 hours, 42% over 2 steps; e) DSC, collidine, EtOAc / ACN (1 / 1), 4 °C to RT, 24 hours, 48% over 2 steps.Scheme 7. Synthesis of (2S,3R,4R)-tBu-Disulphide-OH-Ile. Conditions: a) DMF (dry), RT, overnight, 77%; b) NH2-NH2, ACN, RT, 30 minutes, 85%; c) Cs2CO3(0.2 eq.), MeCN, 60 °C, overnight, 45%; d) LiOH, pH 8-9, THF / H2O (2 / 1), RT; e) TBSCl (4 eq.), imidazole (5 eq.), DMF, 24 hours, 37% (over 2 steps); f) DSC, collidine, EtOAc / ACN (1 / 1), 4 °C to RT, 24 hours, 60%.

[0219] As shown in Scheme 6, reduction of C5 also resulted in 5-member lactone C7 which served as a crucial intermediate for the synthesis of new analogs. Bromine was displaced with azide (Scheme 6) and thioacetate (Scheme 7) nucleophiles. We obtained single-crystal XRD of lactone thioacetate C8 which confirmed the absolute stereochemistry. Lactone C7 served as a key intermediate for accessing azido, amine, epoxy, disulfide, and thiol analogs. All the above-synthesized analogs were incorporated in the amanitin core. We were accordingly able to develop a structure-activity relationship (SAR) study around DHIle which is distinctive and the first of its kind. Scheme 8 shows the coupling reaction between heptapeptide monocycle and dihydroxy-isoleucine analogs for incorporation into α-amanitin where X, Y and Z are as defined in Table 4. As can be seen in Table 4, we also incorporated an example of an azide handle on the peptide backbone for click conjugation, thereby augmenting the translation into viable and new ADCs. Scheme 9 shows a synthesis of a heptapeptide monocyclic precursor with the azide handle.Scheme 8. General preparation of dihydroxy-isoleucine analogs of α-amanitin. Table 4Scheme 9. Synthesis of heptapeptide monocyclic precursor with azide handle.

[0220] TCEP (tris(2-carboxyethyl)phosphine) was also utilized to reduce the azido on the amanitin core which resulted in amine and epoxy analogs (Scheme 10). Scheme 10. Synthesis of (2S,3R,4R)-NH2-OH-Ama and (2S,3R,4R)-Epoxy-Ama analogs.

[0221] Additional α-amanitin analogs shown in Table 5 were prepared by similar methods as those described herein. Table 5III. MTT Assay Against Different Cells IC50 Curves

[0222] The toxicity of the amatoxins was evaluated on Chinese hamster ovary (CHO), human embryonic kidney 293 (HEK 293), cervical-cancer-derived (HeLa), and liver-derived HepG2 cell lines. FIG.3 shows the results of an MTT viability assay on HEK 293 cells, FIG. 4 shows the results of an MTT viability assay on CHO cells, FIG.5 shows the results of an MTT viability assay on HeLa cells, and FIG.6 shows the results of an MTT viability assay on HepG2 cells for A1, A2, A3 and A4 in comparison to α-amanitin. FIG.7 shows the results of an MTT viability assay on HEK 293 cells, FIG.8 shows the results of an MTT viability assay on CHO cells, FIG.9 shows the results of an MTT viability assay on HeLa cells, and FIG.10 shows the results of an MTT viability assay on HepG2 cells for A6 in comparison to α- amanitin. FIG.11 shows the results of an MTT viability assay on HEK 293 cells for A7 in comparison to α-amanitin. FIG.12 shows the results of an MTT viability assay on HepG2 cells for A7 and A8 in comparison to α-amanitin. FIG.13 shows the results of an MTT viability assay on HEK 293 cells, and FIG.14 shows the results of an MTT viability assay on CHO cells for A8 in comparison to α-amanitin. FIG.15 shows the results of an MTT viability assay on HeLa cells for A7 and A8 in comparison to α-amanitin; and FIG.16 shows the results of an MTT viability assay on CHO cells for A7 in comparison to α-amanitin. FIG.17 shows the results of an MTT viability assay on HEK 293 cells for (2S,3R,4R)-SH-OH-Ama (A9) and (2S,3R,4R)-S-S-OH-Ama (A10) in comparison to α-amanitin; FIG.18 shows the results of an MTT viability assay on CHO cells for A9 in comparison to α-amanitin; FIG.19 shows the results of an MTT viability assay on CHO cells for A10 in comparison to α-amanitin; FIG.20 shows the results of an MTT viability assay on HeLa cells for A9 in comparison to α-amanitin; FIG.21 shows the results of an MTT viability assay on HeLa cells for A10 in comparison toα-amanitin-; FIG.22 shows the results of an MTT viability assay on HepG2 cells for A10 in comparison to α-amanitin; and FIG.23 shows the results of an MTT viability assay on HepG2 cells for A9 in comparison to α-amanitin. Table 6 includes a summary of the results. Table 6mantn

[0223] Curiously, the synthesized amatoxins exhibited differential toxicity, hence these analogs could prove to be useful in the selective diagnosis of specific cancers. For example, disulfide derivative of amanitin A6 exhibited less than 3-fold lower toxicity as compared to α- amanitin in HEK293 but in liver-derived HepG2 cells, it was completely inactive. Similarly, fluoro-derivative A2 exhibited almost identical toxicity as α-amanitin in HEK293 however, it was 13-fold less toxic on HepG2 cells. All the α-amanitin analogs tested on multiple cells followed the same trend in that they exhibited differential toxicity on the cells tested.IV. Bioconjugation

[0224] As shown in Scheme 11, the α-amanitin analogs of the present disclosure include those with functionalities useful for bioconjugation with non-limiting examples shown below. Scheme 11. Examples of α-amanitin analogs with exemplary bioconjugation handles. Scheme 12. Synthesis of Thiol-Amanitin based bioreducible disulfide linker.

[0225] Synthetic procedure: A stock solution of the linker shown in Scheme 12 (7 mg) and N-methyl morpholine (4.2 µL) was prepared in 500 µL of anhydrous DMF.150 nM of amanitin analog A9 was quantified and dried in an Eppendorf tube. From the prepared stock solution, 5 µL of the linker (1.5 eq, 225 nM) and 5 µL N-methyl morpholine (2.5 eq, 300 nM) were added to the tube and the reaction was stirred overnight. The reaction progress was monitored via mass spectrometry, upon completion it was diluted with water (0.1 % formic acid) and purified using HPLC. HPLC Purification: Agilent 5 Prep C-18250 × 10 mm (L × ID). Solvent A was 0.1% formic acid H2O (filtered through a 0.2 μm PALL filter). Solvent Bwas 0.1% formic acid MeCN (purchased at HPLC grade, formic acid was then added). Absorbance was monitored simultaneously at 230 nm, 260 nm, and 290 nm. The HPLC method is summarized in Table 7. Retention time tR= 19.80, λmax= 290 nm, calculated [M+Na]+1142.3358; HRMS [M+Na]+1142.3351 (Yield 28%). Table 7

[0226] The amatoxin-linker construct was conjugated to trastuzumab to provide A9 ADC:

[0227] Synthetic procedure: To an Eppendorf tube containing 35 nmol of the NHS-C3-S-S- amanitin shown in Scheme 12 was added 3µL of degassed N,N-dimethylformamide. Then 105 µL of Trastuzumab in 1 × Gibco’s Phosphate Buffered Saline (5 mg / mL) was added directly to the reaction vessel above and the reaction was allowed to mix at ambient temperature for 2 hours with slow rotations. Antibodies were then purified by a Amicon 100kDa MWCO ultracentrifuge filter. The drug-antibody ratio was determined to be 2.0 by MALDI and protein quantification was carried out using Bradford-Lowry to give a recovery of 77%.

[0228] The toxicity of the A9 ADC was evaluated on SK-BR-3 cells in comparison to α- amanitin, amatoxin analogs A9 and A10, and ado-trastuzumab emtansine (KadcylaTM) (FIG.24).

[0229] While the disclosure has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the disclosure is not limited to the disclosedexamples. To the contrary, the present disclosure is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

[0230] All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term. FULL CITATIONS FOR DOCUMENTS REFERRRED TO IN THE DESCRIPTION Bartlett, P. A.; Tanzella, D. J.; Barstow, J. F., Tetrahedron Lett.1982, 23, 619-622. Corey, E. J.; Gross, A. W., Tetrahedron Lett.1984, 25, 495-498. Corey, E. J.; Bakshi, R. K.; Shibata, S., J. Am. Chem. Soc.1987, 109, 5551-5553. Garg, Y.; Tanaka, F., Org. Lett.2020, 22, 4542-4546. Georgi, V.; Wieland, T., Annalen Der Chemie-Justus Liebig 1966, 700, 149-156. Hambira, C. M.; Matinkhoo, K.; Pryyma, A.; Patrick, B. O.; Perrin, D. M., J. Org. Chem. 2021, 86, 5362-5370. Krizan, T. D.; Martin, J. C., J. Am. Chem. Soc.1983, 105, 6155-6157. Lohray, B. B.; Bhushan, V., Angew. Chem.-Int. Edit. Engl.1992, 31, 729-730. Lutz, C.; Simon, W.; Werner-Simon, S.; Pahl, A.; Muller, C., Angew. Chem.-Int. Edit.2020, 59, 11390-11393. Marin, S. D.; Catala, C.; Kumar, S. R.; Valleix, A.; Wagner, A.; Mioskowski, C., Eur. J. Org. Chem.2010, 3985-3989. Matinkhoo, K.; Pryyma, A.; Todorovic, M.; Patrick, B. O.; Perrin, D. M., J. Am. Chem. Soc. 2018, 140, 6513-6517. Mitsumori, S.; Zhang, H.; Cheong, P. H. Y.; Houk, K. N.; Tanaka, F.; Barbas, C. F., J. Am. Chem. Soc.2006, 128, 1040-1041. Pirrung, M. C.; Bakas, N. A., Synlett 2018, 29, 238-242. Pryyma, A.; Matinkhoo, K.; Wong, A.; Perrin, D. M., Chem. Sci.2020, 11, 11927-11935. Rubottom, G. M.; Vazquez, M. A.; Pelegrina, D. R., Tetrahedron Lett.1974, 4319-4322.Rubottom, G. M.; Gruber, J. M.; Boeckman, R. K.; Ramaiah, M.; Medwid, J. B., Tetrahedron Lett.1978, 4603-4606. Siegert, M. A. J.; Knittel, C. H.; Sussmuth, R. D., Angew. Chem.-Int. Edit.2020, 59, 5500-5504. Verkade, J. M. M.; van Hemert, L. J. C.; Quaedflieg, P.; Alsters, P. L.; van Delft, F. L.; Rutjes, F., Tetrahedron Lett.2006, 47, 8109-8113. Wolf, J. P.; Rapoport, H., J. Org. Chem.1989, 54, 3164-3173. Zhao, L.; May, J. P.; Blanc, A.; Dietrich, D. J.; Loonchanta, A.; Matinkhoo, K.; Pryyma, A.; Perrin, D. M., ChemBioChem 2015, 16, 1420-1425. Zhang, H. L.; Mifsud, M.; Tanaka, F.; Barbas, C. F., J. Am. Chem. Soc.2006, 128, 9630-9631.

Claims

CLAIMS What is claimed is:

1. An amatoxin analog comprising a DHIle residue with a sidechain of the formula: , wherein R1is H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2; and R2is H, OR ', NHR ', SR ' or halo; or R1and R2, together with the carbon atoms to which they are attached, form epoxy; each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, or a pharmaceutically acceptable salt thereof, provided that when R1is H or OH, R2is other than H or OH, and when R2is H or OH, R1is other than H or OH; and wherein in the amatoxin analog or the pharmaceutically acceptable salt thereof, one or more available hydrogens is / are optionally replaced with deuterium and / or one or more available hydrogens is / are optionally replaced with fluorine and / or one or more available atoms is / are optionally replaced with its radioactive isotope.

2. The amatoxin analog of claim 1, that is a compound of Formula I: , wherein A is S, S(O), SO2, Se, Se(O) or SeO2; R1is H, OR ', N(R ')2, SR ', halo, -N3, -S-S-R ', imidazole, -CN, -S(O)R ', - ON(R ')2, -N(R ')OR ', -S(O)2R ', -SeR ' or -N(R ')N(R)2; and R2is H, OR ', NHR ', SR ' or halo; or R1and R2,together with the carbon atoms to which they are attached, form epoxy; R3is OR ', NH(OR '), NH-NHR ' or N(R ')2; R4is OR ', NH(OR '), NH-NHR ' or N(R ')2; R5is H or OH; n is an integer from 0 to 4; and each R ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR ' ', SR ' ', halo, -N3and nitrile, wherein R ' ' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, or a pharmaceutically acceptable salt thereof; provided that when R1is H or OH, R2is other than H or OH, and when R2is H or OH, R1is other than H or OH; and wherein in the compound of Formula I or the pharmaceutically acceptable salt thereof, one or more available hydrogens is / are optionally replaced with deuterium and / or one or more available hydrogens is / are optionally replaced with fluorine and / or one or more available atoms is / are optionally replaced with its radioactive isotope.

3. The amatoxin analog of claim 2, having the following stereochemistry: .

4. The amatoxin analog of claim 2 or 3, wherein R4is NH2.

5. The amatoxin analog of claim 2 or 3, wherein R4is -N(R ')2, wherein one R ' is H and the other R ' is C1-20alkyl substituted with -N3.

6. The amatoxin of claim 5, wherein R4is -N(H)CH2CH2N3.

7. The amatoxin analog of any one of claims 2 to 6, wherein R5is OH.

8. The amatoxin analog of any one of claims 2 to 7, wherein R2is -OH (S).

9. The amatoxin analog of any one of claims 2 to 7, wherein R2is -OH (R).

10. The amatoxin analog of any one of claims 2 to 9, wherein n is 0.

11. The amatoxin analog of any one of claims 2 to 9, wherein n is 1.

12. The amatoxin analog of claim 11, wherein R3is 4-OH, 5-OH, 6-OH or 7-OH.

13. The amatoxin analog of claim 12, wherein R3is 5-OH.

14. The amatoxin analog of any one of claims 1 to 13, wherein A is S or (R)-S(O).

15. The amatoxin analog of claim 14, wherein A is S.

16. The amatoxin analog of claim 14, wherein A is (R)-S(O).

17. The amatoxin analog of any one of claims 1 to 16, wherein R1is H, N(R ')2, SR ', halo, -N3, -S-S-R ', wherein R ' is H or C1-6alkyl, or R1and R2, together with the carbon atoms to which they are attached, form epoxy.

18. The amatoxin analog of any one of claims 1 to 16, wherein R1is F, Br, -N3, -S-S-tBu, NH2, SH or -S-S-CH(CH3)CH(CH3)2.

19. The amatoxin analog of claim 1, wherein the amatoxin analog is: (A1); (A2); (A3);or a pharmaceutically acceptable salt thereof.

20. The amatoxin analog of any one of claims 1 to 19 that is not in the form of a salt.

21. The amatoxin analog of any one of claims 1 to 19 that is in the form of a pharmaceutically acceptable salt of the amatoxin analog.

22. An amatoxin-linker construct comprising the amatoxin analog of any one of claims 1 to 21 coupled to a linker, wherein the linker comprises a reactive group R6for conjugating the amatoxin-linker construct to a target-binding moiety.

23. The amatoxin-linker construct of claim 22, wherein the linker is coupled to the amatoxin analog or the salt thereof at a site indicated by R1, R2, R3, R4and / or R5in an amatoxin analog as defined in any one of claims 2 to 21.

24. The amatoxin-linker construct of claim 22 or 23, wherein the linker is coupled to the amatoxin analog or the salt thereof through a moiety obtained from the reaction of R1, R2, R3, R4and / or R5as defined in claim 2 with a complementary functional group on the linker.

25. The amatoxin-linker construct of claim 24, wherein R1and / or R4comprise an N3moiety, the complementary functional group on the linker is an alkyne, and the linker is coupled to the amatoxin analog or the salt thereof through a 1,2,3-triazole.

26. The amatoxin-linker construct of claim 24, wherein R1comprises an SH moiety, the complementary functional group comprises an orthopyridyl disulfide, and the linker is coupled to the amatoxin analog or the salt thereof through a disulfide.

27. A conjugate comprising a target-binding moiety conjugated to an amatoxin analog of any one of claims 1 to 21 or an amatoxin-linker construct of any one of claims 22 to 26.

28. The conjugate of claim 27, wherein the target-binding moiety is a peptide, an oligonucleotide, a lipid, a lipid carrier, a nanoparticle or combinations thereof.

29. The conjugate of claim 27 or 28, wherein the target-binding moiety is an antibody, an antigenbinding fragment thereof, an antibody-like protein, an aptamer, a vitamin, an oligonucleotide, an affibody, a minibody, a lipid, a lipid carrier, a nanoparticle or combinations thereof.

30. The conjugate of claim 27 or 28, wherein the target-binding moiety is an antibody, an antigen-binding fragment thereof or an antibody-like protein.

31. The conjugate of claim 30, wherein the target-binding moiety is an antibody.

32. A pharmaceutical composition comprising the amatoxin analog of any one of claims 1 to 19, or the conjugate of any one of claims 27 to 31 and a pharmaceutically acceptable carrier.

33. A use of an amatoxin analog of any one of claims 1 to 21, a conjugate of any one of claims 27 to 31, for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target.

34. A use of an amatoxin analog of any one of claims 1 to 21, a conjugate of any one of claims 27 to 31, in the preparation of a medicament for treatment of a disease associated with cells presenting a target in a subject in need thereof, wherein the target-binding moiety is specific for the target.

35. The use of claim 33 or 34, wherein the disease associated with cells presenting a target is cancer, an autoimmune disease or a viral infection.

36. A use of an amatoxin analog of any one of claims 1 to 21, a conjugate of any one of claims 27 to 31, for treatment of cancer in a subject in need thereof.

37. A use of an amatoxin analog of any one of claims 1 to 21, a conjugate of any one of claims 27 to 31, in the preparation of a medicament for treatment of cancer in a subject in need thereof.

38. The use of claim 36 or 37, wherein the cancer is breast cancer.

39. A dihydroxyisoleucine (DHIle) analog of the Formula II: whereinR1is as defined in claim 2, a protected form thereof or a precursor thereto; and PG1and PG2are each independently protecting groups.The DHIle analog of claim 39, wherein PG2is tert-butyloxycarbonyl.

41. The DHIle analog of claim 39 or 40, wherein PG2is tert-butyldimethylsilyl.

42. The DHIle analog of any one of claims 39 to 41, wherein R1is as defined in claim 17 or 18.

43. A method of preparing a dihydroxyisoleucine (DHIle) analog, the method comprising:(i) saponification of a lactone of Formula IV to provide a diol of Formula V :(IV) (V) wherein:Rlais H, OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', - ON(R')2, -N(R')OR', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof or a precursor thereto; andPG1is a protecting group; and optionally further comprising:(ii) protection of the diol of Formula V to provide a compound of Formula VI:(V) (VI) wherein:Rlais H, OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', - ON(R')2, -N(R')OR', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof or a precursor thereto; andPG1and PG2are each independently protecting groups; and(ii) convwherein:Rlais H, OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', - ON(R')2, -N(R')OR', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof or a precursor thereto; andPG1and PG2are each independently protecting groups; and wherein each R' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, and wherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR", SR", halo, -N3and nitrile, wherein R" is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cy cloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl.

44. The method of claim 43, wherein R1is other than H, and the lactone of Formula IV is prepared by a method comprising:(i) conversion of the silyl enol ether of Formula VII to the γ-keto-isoleucine of Formula VIII: whereinPG1is a protecting group;R7is -SiR8, wherein each R8is independently Ci-ealkyl or aryl; andRlais H, OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', - 0N(R')2, -N(R')0R', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof a protected form thereof or a precursor thereto; and(ii) reduction of the γ-keto-isoleucine of Formula VIII to obtain the lactone of Formula IV:(VIII) (IV) wherein:PG1is a protecting group;Rlais OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', -ON(R')2, - N(R')OR', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof or a precursor thereto.

45. The method of claim 44, wherein Rlais OH and the conversion of the silyl enol ether of Formula VII to the γ-keto-isoleucine of Formula VIII comprises Rubottom oxidation.

46. The method of claim 44, wherein Rlais Br, and the conversion of the silyl enol ether of Formula VII to the γ-keto-isoleucine of Formula VIII comprises electrophilic bromination of the silyl enol ether of Formula VII to provide a 8-bromo-γ-keto-isoleucine of Formula VIII.

47. The method of claim 46, wherein the method further comprises(a) nucleophilic substitution of Rlain the 8-bromo-γ-keto-isoleucine of Formula VIII; or(b) nucleophilic substitution of Rlain the lactone of Formula IV.

48. The method of claim 47, wherein in (a) the nucleophilic substitution provides a 8-fluoro- γ-keto-isoleucine of Formula VIII and in (b) the nucleophilic substitution provides a lactone of Formula IV, wherein Rlais N3, -SH, -S-S-lBu or -S-S-CH(CH3)CH(CH3)2.

49. A method of preparing a (2S,3R,4S) dihydroxyisoleucine (DHIle) analog, wherein the reduction of the γ-keto-isoleucine of Formula VIII as defined in any one of claims 44 to 48 further or alternatively provides a compound of Formula IX:wherein:PG1is a protecting group; andRlais OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', -ON(R')2, -N(R')OR', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof or a precursor thereto, the method comprising:(i) remwherein:PG1is a protecting group; andRlais 0R',N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', -0N(R')2, -N(R')0R', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof or a precursor thereto ; and optionally further comprising:(ii) protection of the diol of Formula V' to provide a compound of Formula VI': wherein:Rlais H, OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', - 0N(R')2, -N(R')0R', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof or a precursor thereto; andPG1and PG2are each independently protecting groups; and(iii) conversion of the compound of Formula VI' to the NHS ester of Formula II':wherein:Rlais H, OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', - ON(R')2, -N(R')OR', -S(O)2R', -SeR' or -N(R')N(R)2, a protected form thereof a or a precursor thereto; andPG1and PG2are each independently protecting groups.

50. The method of claim 49, wherein Rlais F.

51. The method of any one of claims 44 to 50, wherein the silyl enol ether of Formula VII is prepared by a method comprising reacting a γ-keto-isoleucine of Formula X with a silane of Formula XI in the presence of a base:(X) (VII) wherein:PG1is a protecting group; each R8is independently C1-6alkyl or aryl; andR9is a hydrolysable group.

52. The method of claim 51, wherein the compound of Formula X is prepared by a method comprising: removal of the p-methoxy phenyl (PMP) group from a γ-keto-L-isoleucine of Formula XII followed by protection of the amino group to provide the compound of Formula X:

53. The method of claim 43, wherein R1is H, and the lactone of Formula IV is prepared by a method comprising:(i) reduction of aγ-keto-isoleucine ofFormulaXII to provide a lactone of Formula IV(a):(XII) and protection of the lactone of Formula XV(a) to provide the lactone of Formula IV.

54. The method of claim 52 or 53, wherein the γ-keto-L-isoleucine of Formula XII is prepared by a method comprising:(i) L-proline-catalyzed Mannich reaction of p-methoxyphenyl-iminoester of Formula XIII with butanone to provide γ-keto-L-allo-isoleucine of Formula XIV:; and(ii) catalytic epimerization of the γ-keto-L-allo-isoleucine of Formula XIV to provide the γ-keto-L-isoleucine of Formula XII:(XII)55. The method of claim 54, wherein the p-methoxyphenyl-iminoester of Formula XIII is prepared by reaction of p-anisidine with ethyl glyoxalate.

56. The method of any one of claims 43 to 56, wherein the method is for preparing a dihydroxyisoleucine (DHIle) analog of Formula 111(a):OH NH2the method comprising deprotection of the diol of Formula V or Formula V' to provide the compound of Formula III.

57. A use of a compound of any one of claims 39 to 42 or an NHS ester of Formula II or Formula II' prepared by a method of any one of claims 43 to 55 in the preparation of an amatoxin or an amatoxin analog.

58. A method of preparing an a-amanitin or an a-amanitin analog, the method comprising coupling a compound of any one of claims 39 to 42 or an NHS ester of Formula II or Formula II' prepared by a method of any one of claims 43 to 55 to a monocyclic heptapeptide a- amanitin or a-amanitin analog precursor, followed by deprotection and macrolactamization.

59. The method of claim 58, wherein PG is tert-butyloxycarbonyl and the conditions for deprotection comprise HC1 having a concentration of about 1 M in a solvent comprising Et2O.

60. The method of claim 60, wherein R1is N3, and the method further comprises reduction of the a-amanitin analog to convert R1into an NH2and / or an epoxide.

61. A dihydroxyisoleucine (DHIle) analog of the Formula III: whereinR1is OR', N(R')2, SR', halo, -N3, -S-S-R', imidazole, -CN, -S(O)R', -ON(R')2, -N(R')OR', -S(O)2R', -SeR' or -N(R')N(R)2; and each R' is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, wherein one or more available carbon atoms in the C1-20alkyl, C2-20alkenyl and C2-20alkynyl is optionally replaced by a heteroatom, andwherein the C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, heterocycloalkyl and heteroaryl is optionally further substituted with one or more groups selected from OR", SR", halo, -N3and nitrile, wherein R" is independently H, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-20cy cloalkyl, C6-30aryl, heterocycloalkyl or heteroaryl, provided that R1is not OH.

62. The DHIle analog of claim 61, having the following stereochemistry:

63. The DHIle analog of clai mistry:

Citation Information

Patent Citations

  • Non-natural amatoxin-type antibody conjugate

    US20210030887A1

  • Amatoxin-conjugates with improved linkers

    WO2012041504A1

  • Amatoxin derivatives

    WO2014135282A1

  • Antibody drug conjugates having derivatives of amatoxin as the drug

    WO2017210288A1

  • Amatoxin antibody-drug conjugates and uses thereof

    WO2020216947A1